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Introduction 
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Health economics and economic evaluations 
Health economics is an important and growing field within health care research. The 
field of health economics focuses on the efficient use of scarce resources. Scarcity is 
the tension between unlimited needs and the limited possibilities for meeting these 
demands. Even though society wants to have the best care for its population, budg-
etary constraints are a given fact. Consequently, health care resources should be 
used as efficiently as possible [1, 2]. 
One of the main questions in health economics is for which health care technologies 
the scarce resources should be used [2]. In economic evaluations the costs and con-
sequences of two or more alternative health care technologies are compared [3, 4]. 
The consequences in an economic evaluation can vary from clinical effects to 
health-related quality of life. When selecting the alternatives it is important to se-
lect carefully the alternatives with which the new technology will be compared. 
Preferably, the chose alternative is the best available alternative, or the standard 
treatment [2-4]. 
Economic evaluations are carried out to support the decision making process - for 
example, the decision regarding the reimbursement of specific technologies or 
whether a technology should be considered for use in clinical practice. This is in line 
with the aim of economic evaluations to help the decision making process in maxi-
mizing the benefits given the resources available [2-4]. 
A growing number of jurisdictions are using economic evaluations to guide their 
decision making about reimbursement for health care technologies, especially new 
pharmaceuticals [5, 6]. Jurisdictions can be perceived as any settings where a need 
can be identified for local cost-effectiveness estimates. This is often a country, but it 
may also be a region within a country or a particular payer [7]. In many countries, 
the request for economic data is often dictated by national guidelines for perform-
ing pharmacoeconomic evaluations [8]. Performing evaluations according to these 
guidelines creates financial, personnel and time pressures on study sponsors and 
researchers, especially when the guidelines insist on using local data or specific 
methodologies [7]. It is not always possible to perform studies locally [9]. This is a 
problem in particular for small countries and for low and middle income countries 
as these countries have limited resources for carrying out economic evaluations. As 
a result, most health care technologies are evaluated in a limited number of jurisdic-
tions and decision makers may end up with data collected elsewhere [10]. Unfortu-
nately, the findings of cost-effectiveness analysis do not travel well because of dif-
ferences between health care systems [11]. This raises the question if and to which 
extent economic evaluations from one jurisdiction can be easily transferred and 
used for valid policy decision making in another [12]. 
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Transferability of economic evaluations 
Transferability has no clear-cut definition and it is often confused with generalisabil-
ity. According to Späth et al. (1999) the results of a study are transferable if poten-
tial users can assess whether the results apply to their settings and adapt them if 
necessary [9]. The ISPOR Task Force on Transferability states that economic evalua-
tions are generalisable if they can be applied without adjustment to other settings. 
Data are transferable if they can be adapted to apply to settings other than the 
study country [7]. Drummond and Pang (2005) defined transferability as the lack of 
generalisability from place to place [13]. These definitions indicate that transferabil-
ity is always between settings and is closely related to generalisability. In this thesis, 
the definition of the ISPOR taskforce will be used. This means that in this thesis, 
generalisability is defined as the application of data to other settings without adap-
tations; transferability is defined as the application to other settings with adapta-
tions. 
Considering the growing use of economic evaluations, resource constraints and the 
time needed to carry out economic evaluations for each specific choice to be made 
between technologies, the importance of transferring results is increasing. Eco-
nomic evaluations are most useful in the settings in which the study was conducted. 
The results can probably not be used in another setting without any adaptation, but 
the value of economic evaluations would increase greatly if studies could be trans-
ferred with ease [6]. 
There is enough evidence available to assume that cost-effectiveness estimates can 
vary across settings and countries [14]. These differences are the results of so-called 
transferability factors that affect the results of economic evaluations [15]. These 
factors that influence the transferability are likely to generate variability in cost-
effectiveness results across jurisdictions [16, 17]. However, the interplay of various 
factors can hinder attempts to adapt the data so that it can be transferred across 
jurisdictions [18]. In the literature several lists and classifications of these transfer-
ability factors can be found, differing in length and elaborateness [10, 14, 17]. How-
ever, the most frequently mentioned factors are demography and epidemiology of 
disease, availability of health care resources, clinical practice variation, incentives to 
health care providers and institutions, relative prices and population preferences 
[14]. In addition, differences in methodological factors such as the perspective, dis-
count rate and time horizon of a study could also hinder the transferability. More-
over, it has to be kept in mind that transferability is not a dichotomous concept: the 
transferability of data can be classified in degrees of complexity. Some parameters 
of economic evaluations can be transferred fairly easy, while other components will 
take more effort [17]. 
The transferability of economic evaluations can for example be hindered by differ-
ences in the study perspective and differences in case-mix. The modelling study of 
Chapter 1 
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Essers et al. [19] is an example which showed that calculating the costs using a dif-
ferent study perspective could change the conclusion. In this study a UK-based 
model on the cost-effectiveness of trastuzumab for the adjuvant treatment of 
breast cancer was transferred to the Netherlands. When diagnosing the transfer-
ability of the model, it became clear that the health care perspective used in the UK 
did not correspond with the societal perspective required in the Netherlands. 
Switching to the societal perspective in the Dutch model resulted in that the ex-
perimental treatment became dominant over the control treatment [19]. In the 
study of Esteban et al. [20] in twenty countries on mechanical ventilation it was 
showed that older mechanically ventilated patients had a lower survival of the in-
tensive care unit and a lower overall survival, while the treatment was equal to 
younger patients [20].   
The transferability of all these factors or of entire economic evaluations can be 
taken into account when either performing or interpreting economic evaluations. 
Five different stages can be distinguished in which different transferability issues 
can be taken into account: these stages are described in Figure 1. When “Perform-
ing economic evaluations”, there are three opportunities for increasing transferabil-
ity, namely when designing, analysing and reporting the study [21]. It is possible in 
the design stage to anticipate the need for transferring the findings, and, at the de-
sign stage, to take several precautionary measures to increase the transferability - 
for example, by selecting a variation of study sites, including a real world compara-
tor, and including a societal perspective of the study. When analysing the results the 
focus should be on variability of the results in a wide range of settings.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Transferability issues in different stages 
 
In multinational trials data are collected in multiple countries, after which these 
data should be analysed in such a way that the results are relevant for all included 
jurisdictions. In reporting the results an attempt could be made to anticipate the 
need for transferring the data: in general it is necessary to be transparent about 
every step in the economic evaluation. In the end the main objective is to help deci-
sion makers to diagnose whether or not a given study is relevant to their decision 
design analysis reporting diagnosis adaptation
Performing economic evaluations Interpreting economic evaluations
PUBLICATION
POLICY 
DECISION
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making setting [21]. Two stages can be identified when “Interpreting economic 
evaluations” in which the transferability of data plays a role. In the diagnosing stage 
different elements of an economic evaluation are assessed on their transferability. 
This can be carried out by assessing the transferability of the collected data, and in 
particular the factors that are likely to differ between settings. The diagnosing stage 
is very important for decision makers as they must consider whether the costs and 
effects estimates collected in other jurisdictions can be used for their own setting. 
However, for many factors it is not clear yet whether or not they can be transferred 
easily across jurisdictions. When the data are not considered to be transferable new 
data have to be collected or the data must be adapted. In the adaptation stage the 
data that cannot be transferred are adapted to the new setting. For example, unit 
costs have to be adapted to the new setting by replacing the old costs by the costs 
of the same service in the new setting. 
Aim and outline of the thesis 
In this thesis several aspects related to the diagnosis of transferring economic eva-
luations across jurisdictions will be discussed. All research in this thesis looks at the 
diagnosis of international aspects of economic evaluations, meaning that transfer-
ability problems related to differences between countries and related to multina-
tional trials are not taken into account. The objective of the thesis is to explore in 
the diagnosis stage of economic evaluations, methods for transferring cost-
effectiveness estimates and costs and effect values between jurisdictions. 
Chapter 2 Transferability issues 
In Chapter 2 an overview will be given of the current state of the literature regard-
ing the transferability of economic evaluations. Due to the limited availability of lo-
cal data and increasing pressure to use economic data, more and more often deci-
sion makers accept foreign data or data from multinational studies for their decision 
making process. Foreign data are sometimes used without a critical examination of 
whether data are really transferable from one jurisdiction to another. This can cause 
problems and these problems, which are described by giving an overview of the 
current literature on the transferability of economic evaluations. 
Chapter 3 Assessment of the transferability of economic evaluations 
In Chapter 3 the following research question will be answered: To which extent is 
Welte’s model a valid method for assessing the transferability of economic evalua-
tions? In the last decade several methods have been developed for assessing the 
Chapter 1 
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transferability of economic evaluations. Most methods use a kind of checklist to 
assess the article or report [10, 22-26].These methods can also be used in the analy-
sis stage of an economic evaluation to assess the transferability of the data. By using 
one of the methods in the design stage of a study, the transferability of the col-
lected data could be increased. However, until now it is not clear if the methods 
really help in assessing the transferability of economic evaluations, resulting in un-
certainty about whether applying one of these methods will lead to different con-
clusions than those obtained when directly using the data of an economic evalua-
tion in another setting. However, none of the methods have been tested in real life. 
In this chapter the testing of Welte’s model will be discussed. 
Chapter 4 The transferability of recommendations on lost productivity 
Chapter 4 will focus on the following research question: What do the national 
pharmacoeconomic guidelines recommend regarding the identification, measure-
ment and valuation of lost productivity?  Until now, only limited information is 
available on how this potential element of economic evaluations should be in-
cluded, according to national guidelines. In addition, for several chronic diseases, 
the costs of lost productivity are higher than the health care costs. It could there-
fore be beneficial to reimburse health care technologies that result not only in 
lower health care costs, but also lower the lost productivity of the patient [27, 28]. 
In a growing number of countries pharmacoeconomic guidelines have been devel-
oped to indicate which requirements economic evaluations should fulfil. This is es-
pecially important if the results will be used in determining which technologies 
might be eligible for reimbursement [8, 29]. At the moment more than thirty na-
tional guidelines are available and that number is still rising [8]. Developing guide-
lines is a continuous process and recommendations can change and may vary across 
settings, leading to the question of whether the main recommendations differ [6]. 
This is of particular interest for topics on which no international consensus exist, as 
diverse recommendations could result.  
Chapter 5 Real time data of lost productivity in four European countries 
In the fifth chapter the research question is answered: to what extent is lost produc-
tivity, both being absenteeism and presenteeism, influenced by differences in coun-
tries? Besides the possible different recommendations regarding the inclusion of 
the value of lost productivity other problems may occur when transferring these 
data. Lost productivity data is collected using different kinds of questionnaire, which 
use different methods for identifying lost productivity; this makes it hard to com-
pare the data. To be able to compare the data collected from different countries the 
same questionnaire should be used. However, it is not clear if lost productivity data 
Introduction 
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can be easily transferred between jurisdictions. Previous research [27, 28] has indi-
cated that between country differences can be found, but these differences can be 
the result of different measurement methods. 
Chapter 6 Transferring utilities 
In the sixth chapter the following research question will be answered: what are the 
effects of differences in national EQ-5D value sets on absolute and marginal utilities 
of health states, and to what degree can these differences be explained by meth-
odological factors? It is assumed that the clinical effectiveness of health care tech-
nologies is equal across neighbouring countries, because the biological differences 
are negligible [15]. However, it is not clear if this is also true for health state prefer-
ences and the resulting utilities. In daily practice, transferring utilities has been 
given less attention than transferring cost data, with the result that utilities are of-
ten transferred without hesitation. It is not clear whether the utilities of the EQ-5D 
are easily transferable or not. This generic instrument for measuring health-related 
quality of life in economic evaluations has been developed to compare utilities 
across countries. Several value sets are available to calculate the utility for specific 
health states. The utilities derived with the EQ-5D are often used directly without 
any adaptation and it is not clear if this practice is advisable. However, the value 
sets differ and it is unclear whether this is caused by cultural or methodological dif-
ferences [30]. 
Chapter 7 Discussion 
The final chapter will discuss the main findings and conclusion of this thesis. Fur-
thermore, a general discussion and considerations related to the overall research 
will be offered. Several recommendations for further research and for decision 
makers on dealing with transferability issues will be presented. 
Chapter 1 
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Introduction 
Decision makers and health care professionals, such as hospital pharmacists, are 
under increasing pressure to understand and manage the health consequences and 
economic impact of pharmaceuticals that are new to a health care market [1]. A 
growing number of jurisdictions request economic data in support of their decision-
making procedures for the pricing and/or reimbursement of pharmaceuticals [2]. 
However, economic evaluations, of which cost-effectiveness analysis is the most 
commonly used method, are costly and time consuming which makes it not always 
possible to carry them out locally [3]. The increasing demand for cost-effectiveness 
analysis, limited research resources, time constraints and a shortage of evidence 
creates pressure to transfer data across jurisdictions [3, 4]. Some of the jurisdictions 
requiring data of economic evaluations in support of submissions for public reim-
bursement of pharmaceuticals have pointed out that the data need to be relevant 
to the local setting. However, little advice is offered on the approach to be adopted 
[5]. Unfortunately, economic evaluation findings, particularly costs, do not transfer 
well because of differences in health care and economic systems [6]. The transfer-
ability of economic evaluations is not only an issue between countries, but also 
within countries [7]. Therefore, decision makers commonly want conformation that 
a given economic evaluation is transferable to their particular population and 
treatment settings [8]. 
Although the concept of generalisability is related, it is regarded as something dif-
ferent. Generalisability is defined as the extent to which the results of a study can 
be generalized to the population from which the sample was drawn. Whereas, 
transferability is conceptualized as the extent to which the results of a study, as it 
applies to a particular setting, hold true for a different population or setting [9]. Ac-
cording to Späth et al. (1999) the results of an economic evaluation are transferable 
if potential users could assess whether the results apply to their settings and adapt 
them if necessary [3]. According to the ISPOR task force (2009) data are considered 
transferable if they can be adapted to apply to other settings or jurisdictions [2]. 
It seems unrealistic to generate cost-effectiveness or cost-utility data for every deci-
sion making context and therefore strategies for dealing with transferability issues 
need to be developed [5]. There are countless sources of variation to consider when 
adapting the economic evaluation results to a particular health care setting which, if 
not addressed, might lead to the inefficient implementation of new pharmaceuticals 
[1]. Even among countries with relatively similar health care systems there are dif-
ferences in the results of economic evaluations across countries [10]. For example, 
differences between neighbouring countries regarding the price of pharmaceuticals, 
variation in resource use or variation in the prescription and dosage of pharmaceu-
ticals [11]. 
Transferability issues 
 21 
Problems related to transferability factors 
Transferability factors are factors that are likely to generate differences in economic 
evaluation results between settings or affect the transferability of economic evalua-
tion data [12, 13]. Several factors have an influence on the differences between 
countries, which results in variation of the cost-effectiveness of pharmaceuticals 
from place to place [12, 14]. The factors can be classified into five different catego-
ries of characteristics, based on characteristics of the patient, the disease, the pro-
vider, the health care system and economic evaluation-methodology used. The fol-
lowing factors are often referred to: demographics of the population; epidemiology 
of disease; clinical practice; experience, education and training of the health care 
professionals; incentives for providers; absolute or relative prices (if the relative 
prices of pharmaceuticals differ between countries then the relative cost-
effectiveness will also differ); available resources and services; organization of de-
livery system; available treatment options (the so-called comparators in an eco-
nomic evaluation); perspective of the economic evaluation and study factors [5, 13]. 
From the above, it could be argued that the transferability of the results of an eco-
nomic evaluation is influenced by a large variety of factors. According to Goeree et 
al. (2007) there are three main factors that are commonly advocated when transfer-
ring data across jurisdictions: unit costs; resource utilization or practice patterns and 
clinical efficacy [13]. Other important factors that have been mentioned are: avail-
ability of health care resources and population preferences [10]. It is widely ex-
pressed that there are sometimes substantial differences in unit prices across juris-
dictions. Most researchers state that at least the unit prices need to be replaced 
when transferring economic evaluations. However, not only the differences in abso-
lute prices are important, but also the relative price differences. Furthermore, there 
are sometimes important differences in clinical practice across jurisdictions, which 
can have a significant impact on the cost-effectiveness of an intervention [13]. All 
these differences should be taken into account when transferring economic evalua-
tions across countries. Most research on transferability has been focusing on the 
costing side of economic evaluations. On the effect side, the EQ-5D is a frequently 
used instrument to measure health-related quality of life in economic evaluations, 
which was developed to compare the population preferences for health states 
across countries. At the moment the EQ-5D has seventeen country-specific value 
sets, which can be used to calculate the utilities for specific health states [15, 16]. 
Nevertheless, utility estimates from foreign studies are often used directly for cost-
effectiveness estimates, without adapting by applying the appropriate national 
value set. However, recent research has indicated that using utilities obtained in 
one jurisdiction are often not equal to the valuation of health states of the general 
population in another jurisdiction, which can lead to misleading results. It is there-
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fore not advisable to transfer utilities from one country to another without any ad-
justment [16]. 
Possible solutions for using economic evaluations from abroad 
For each evaluation it is necessary to define in advance a clear and appropriately 
specified decision problem. This requires a description of the patient population and 
the comparators to the new technology. It is possible that a specified decision prob-
lem related to new pharmaceuticals vary between jurisdictions. The first reason is 
that licences can differ between countries and this can affect the clinical applica-
tions of the new product, or of the comparators. A second reason relates to the dif-
ferences in treatment patterns, where interventions used in one country are not 
used in another, which affect the choice of comparators [2]. 
The checklist by Boulenger et al. (2005), forty-two questions, and a sub-checklist, 
sixteen questions, assesses the level of reporting of transferability information. For 
each question the answers are classified as: ‘yes’, ‘partially’, ‘no/no information 
provided’ or ‘not applicable’. The responses are given the following score: 1 for 
‘yes’, 0.5 for ‘partially’ and 0 for ‘no/no information’. When the response to a ques-
tion is ‘not applicable’, the question is excluded from the scoring by reducing the 
denominator accordingly. A summary score can be derived using the following for-
mula: 1/n-x Σi Si * 100, n= number of questions, x = number of questions with the 
response ‘not applicable’ and S = score for each question. The answers to the ques-
tions lead to a transferability information score. In the article by Boulenger et al. 
(2005) was the mean score 66.9 ± 13.6% and the scores on the checklist and the 
sub-checklist, which focus specifically on transferability, were comparable. How-
ever, no standard is available and therefore it is difficult to determine what a score 
indicates [17]. An assessment of the transferability of decision-analytic models can 
be carried out by paying attention to the four topics as described by Urdahl et al. 
(2006). These topics are chosen to assess whether articles reporting decision-
analytic models provide enough information to enable decision makers in different 
jurisdictions to fully appreciate the variability of results according to location and be 
able to apply the evaluation to their own setting. The topics are: definition of target 
decision maker or jurisdiction, transparent reporting of model specification, rele-
vance of data inputs to target decision maker or jurisdiction and assessment of ro-
bustness of model to variation in data inputs within and between jurisdictions. Ac-
cording to Urdahl et al. (2006) most studies stated the target decision maker or ju-
risdiction, but less information was provided on the other three topics [18]. 
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Figure 1 Steps for determining appropriate methods for adjusting cost-effectiveness informa-
tion (based on: ISPOR Task Force on Transferability of economic evaluation across jurisdictions 
[2]) 
 
In Figure 1, three steps are described that consider the availability of data and helps 
to determine whether simple or more elaborate methods for adjusting results of 
economic evaluations to a particular jurisdiction are needed [2]. At first, an eco-
nomic evaluation must first meet three general knock-out criteria, as stated in 
Welte et al. (2004) [4].These criteria help to determine which studies can be trans-
ferred to the decision country and which not. Both (1) the experimental technology 
and (2) the comparator(s) should be relevant in the jurisdiction of interest; other-
Consider collecting other data 
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Step 1 
Is the study of acceptable  
quality and relevant to the decision 
problem? (see Welte et al 
criteria) 
No 
 
Yes 
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applying local unit costs, using na-
tional health state valuation 
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Are the treatment  
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local treatment 
 patterns? 
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No 
 
Consider using statistical  
methods 
 
 
 
 
Step 3 
Is the study based on data  
from a multi-location  
randomized trial? 
Yes 
 
No 
 
Develop a decision-analytic model 
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wise the cost-effectiveness results are irrelevant. Furthermore, if (3) the methodo-
logical quality of the study does not meet the local standards, the transfer of the 
estimate is not valid. When the economic evaluation does not fulfil these three cri-
teria, then the results are not transferable because the starting point of the evalua-
tion is irrelevant [2, 4]. 
In the second step, the most important transferability factors, as ascertained by 
Welte et al. (2004), will be used to determine the level of correspondence between 
study country and decision country to decide if the economic evaluation is transfer-
able. It is possible that only a simple adjustment procedure is necessary to transfer 
the economic evaluation results to the decision country. Therefore, the transferabil-
ity factors should be verified to find out which adjustments may be necessary to be 
able to use the results. For instance, the setting where a patient is treated (e.g. hos-
pital setting or family physician) can differ between countries. Therefore, practice 
variation between jurisdictions may make the transferability of the results of eco-
nomic evaluations impossible without adjustment, for instance costs. Furthermore, 
differences in absolute and relative prices make recalculation necessary and there-
fore jurisdiction-specific price data might be required. In addition, the definition of 
the time horizon of the analysis can be a problem as the guidelines might differ be-
tween jurisdictions. Other characteristics of existing economic evaluations for which 
adjustment may be required, concern the perspective that is used, the discount rate 
applied and value set used for the valuation of health states [2, 4, 15]. 
When it becomes clear that the available economic evaluation results are not di-
rectly transferable through simple adjustments the last step should be considered. 
Step three indicates that there are two remaining options. If the jurisdiction of in-
terest has participated in a multinational clinical trial in which data on resource use 
and/or costs have been collected, then the preferred strategy would be to analyze 
the individual patient data. When the individual patient data are available there are 
some analytic approaches to calculate adjusted cost-effectiveness estimates for this 
jurisdiction. The analytic approaches address two sets of objectives. The first is to 
evaluate whether there is evidence of heterogeneity across jurisdictions included in 
the trial and to explore the potential sources of heterogeneity. The second objective 
is to obtain estimates of incremental resource use, cost and/or cost-effectiveness 
that are suitable for decision making within particular jurisdictions that may of may 
not have been included. When the economic evaluation was undertaken outside 
the jurisdiction of interest, a modelling approach would be required, using as much 
clinical and cost data as possible from the jurisdiction of interest. In general, the 
structure of a model will be determined by the clinical course of a disease and the 
effects of (a set) interventions. Depending on the type of model selected, the struc-
ture embodies the choice of states/pathways and how they interact. However, 
there may be legitimate differences in model structure between jurisdictions and 
this is related to differences in the specified decision problem [2]. 
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Conclusion 
The increasing pressure on health care decision makers to use scarce health care 
resources more efficient has resulted in an enlarged demand for evidence from 
economic evaluations. Nevertheless, conducting an economic assessment of each 
intervention for each jurisdiction will result in inefficient use of evaluation re-
sources. As a result decision makers will increasingly be looking at the applicability 
of using economic evaluation results from abroad. However, the literature indicates 
that there is enough evidence that economic evaluation results can vary across ju-
risdictions and that there are a number of factors that may be a threat to the trans-
ferability of economic evaluations. Thus, decision makers should be aware of the 
factors affecting the transferability of data from another jurisdiction, as we de-
scribed in this paper. To our opinion, the most feasible option will be to use the 
steps as proposed by the ISPOR task force. 
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Abstract 
Objective: One of the existing methods to asses the transferability of economic 
evaluations is the model of Welte, which is a decision chart method that includes 
general and specific knock-out criteria and a transferability checklist. This study aims 
to test Welte’s model with the help of a case study. 
Methods: In this study, foreign studies were transferred to the Netherlands and 
then compared with a Dutch reference study. In the case study the cost-
effectiveness of physiotherapy was compared with a multidisciplinary treatment. 
With the help of a systematic search several foreign studies could be identified. 
Based on these foreign studies two different predictions were produced for the 
Netherlands. In the “all studies prediction” all foreign studies were used. In the 
“Welte’s model prediction” only the foreign studies were used which passed the 
general and specific knock-out criteria. Both predictions were compared with the 
Dutch reference case. 
Results: A total of fourteen non-Dutch studies were identified. Seven studies did not 
pass the general knock-out criteria and one study did not pass the specific knock-
out criteria. As a result fourteen studies were included in the “all studies prediction” 
and six studies in the “Welte’s model prediction”. The predictions yielded different 
results and the “Welte’s model prediction” proved better on costs than the “all 
studies prediction”. 
Discussion: Application of Welte’s model does influence cost and effects estimates 
when transferring economic data between countries. However, more cases should 
be subjected to the Welte transferability model before a final conclusion can be 
drawn. 
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Introduction 
International interest in the economic evaluation of interventions in health care is 
growing [1]. In recent years, economic evaluations have become more decisive in 
the process of decision making in health care all over the world [2]. Using data, 
methods or results from published studies abroad can save time compared to con-
ducting a new economic evaluation in your own country. When studies cannot be 
performed nationally, for instance because of small number of patients in a country, 
it may even be the only possibility. Decision makers can use economic evaluations in 
at least two ways: ‘uncorrected’ by applying the conclusions directly or ‘corrected’ 
by applying the methods and data that are applicable and substituting local meth-
ods and data for those that are not [3]. However, every country has its own unique 
health care structure. This raises the question whether the results of economic stud-
ies can be transferred from one country to another without any correction [2]. 
Transferability may be defined as the generalisability of study results from one pol-
icy setting to another or from one country to another [4]. 
The extrapolation of the results of economic evaluations to another setting is not 
straightforward [1]. HTA-researchers agree about the most important factors that 
influence the transferability of study results [1-6]. These factors are: demography of 
the population, epidemiology of diseases, availability of health care resources and 
variations in clinical practice, incentives to health care professionals and institu-
tions, relative prices and population preferences [4]. Besides that, cost-effectiveness 
results for pharmaceuticals vary between Western European countries and these 
variations are not systematic. One of the main causes appeared to be the price of 
the major cost drivers. However, the main factor is whether resource use is allowed 
to vary across countries and therefore analysts should provide strong arguments for 
pooling resource use data [7]. These factors make a complete extrapolation of re-
sults from one country to another impossible [1]. 
The transferability factors also hinder the transfer of an incremental cost-
effectiveness ratio (ICER) without any adjustments, because it is assumed that the 
costs always differ between countries. These differences can be associated with 
differences in health care consumption and prices. Therefore, the cost data should 
always be adjusted to the decision country. The effectiveness data may be transfer-
able from place to place. This is due to the assumption that the differences in out-
come resulting from interventions between patients in countries are small and 
therefore the effectiveness of treatments is the same [4, 8]. 
In the last fifteen years much has been written about these factors influencing the 
transferability, but the discussion remained rather theoretical. To our knowledge, 
this study is one of the first to test the theoretical transferability factors in an ex-
perimental setting. By testing the theoretical assumptions, the pitfalls and problems 
related to the transfer of studies to other settings will be identified. 
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One of the existing methods to assess the transferability of economic evaluations is 
the model of Welte. The other existing and published methods to assess the trans-
ferability are those of Boulenger et al. [3], Urdahl et al. [9] and Nixon et al. [10]. The 
methods of Boulenger et al. [3] and Nixon et al. [10] have no clear cut-off points to 
decide if the economic evaluation is transferable or not. The method of Urdahl et al. 
[9] is especially developed for assessing method-based economic evaluations. 
Welte’s model was chosen because it has clear cut-off points and can be used for 
the assessment of both empirical and method-based economic evaluations. The 
research question is: To which extent is Welte’s model a valid method to assess the 
transferability of economic evaluations? Consequently, the objective of this study is 
to test Welte’s model. This testing will be carried out by means of a case study. 
Theory: short description of Welte’s model 
The model of Welte is one of the first general and the oldest method that is devel-
oped to decide which studies are transferable [6]. Before Welte’s model, only mod-
els for specific diseases were available, cf. Caro et al. (1999) [11]. Welte’s model is a 
transferability decision chart method that includes general and specific knock-out 
criteria and a transferability checklist. With the help of these general and specific 
knock-out criteria it is possible to determine which studies can be transferred to the 
decision country and which can not. A study or article must first meet three general 
knock-out criteria: 1) the evaluated technology should be comparable to the one 
that shall be used in the decision country, 2) the comparator should be comparable 
to the one that is relevant to the decision country and 3) the study should possess 
an acceptable quality. When a study has passed these general knock-out criteria, 
the specific knock-out criteria will be used to determine which parts of the studies 
are transferable. The specific knock-out criteria are listed in Table 1. 
 
Table 1 Specific knock-out criteria of Welte’s model 
 
Transferability factors Factors 
Methodological characteristics perspective
1
; discount rate; medical cost approach
1
; produc-
tivity cost approach
1
 
Health care characteristics absolute and relative prices; practice variation; technology 
availability 
Population characteristics incidence/prevalence; case-mix; life expectancy; health-
status preference; acceptance, compliance and incen-
tives to patients; productivity and work-loss time
1
; dis-
ease spread 
Source: Welte et al., Pharmacoeconomics 2004 22(13), 857-876. 
1) These factors have a high relevance in this study 
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These factors or specific knock-out criteria in the transferability checklist are used to 
determine the correspondence between the study country and the decision coun-
try. This is carried out in three steps. First, the relevance of each transferability fac-
tor is determined. In the second step, the level of correspondence between the 
study country and the decision country is estimated. For the last step, the checklist 
is applied to determine the expected effect of the factor on the cost-effectiveness 
ratio (CER). The estimation of the CER depends on the relevance of the factors and 
the correspondence between the study and decision country. When both are high, 
the estimation will be unbiased. In the case of a low correspondence, the estimation 
of the CER will be biased. After these three steps, it can be decided which adjust-
ments are necessary to transfer the foreign studies [6]. 
Methods 
Case selection 
To test Welte’s model a case was selected by following the next steps. First, topic 
for the case was searched for using Medline, whereby the topic of the case study 
should fulfil the following criteria: cost-benefit-analysis [mesh], study not older than 
five years (py>2002), randomised controlled trial (rand∗ in ti or rand∗ in ab or rct in 
ab or rct in ti), incremental comparison of treatments (differen∗ in ti or differen∗ in 
ab or increment∗ in ti or increment∗ in ab or rati∗ in ti or rati∗ in ab), societal per-
spective (soci∗ in ti or soci∗ in ab or indir∗ in ti or indir∗ in ab or non-medi∗ in ti or 
non-medi∗ in ab), and cost-utility analysis (util∗ in ab or util∗ in ti). These search 
criteria resulted in seventy-four results, whereby the abstracts were checked if they 
fulfilled the following criteria: fulfilled the studies the criteria of the Medline search, 
performed in the Netherlands, only empirical and no modelling studies and only 
single country studies. 
Only a limited of Dutch studies satisfied these criteria (N=15). The full text article 
was read and based on these articles, studies indicating it was the first economic 
evaluation on this topic were considered unsuitable and removed. For the remain-
ing studies (N=9) Medline was searched to find comparable foreign studies, which 
had to be at least five foreign studies for each topic. The foreign studies should fulfil 
the same criteria as the Dutch study, but there were some extra requirements, 
namely: equal disease, article should be written in English, study performed outside 
the Netherlands, studies performed in different foreign countries, ‘comparable’ in-
tervention or experimental treatment. Studies were excluded if they were multina-
tional trials. Based on this search strategy, only one case study remained, namely 
the study of Van der Roer et al. [12] (Table 2). 
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Table 2 Selection of the case study  
 
Step 1 Selection based on key-words 
Search criteria Results 
#1 cost-benefit-analysis [mesh] 43206 
#2 rand∗ in ti or rand∗ in ab or rct in ab or rct in ti 458732 
#3 differen∗ in ti or differen∗ in ab or increment∗ in ti or increment∗ in ab or 
rat∗* in ti or rati∗ in ab 
3055267 
#4 soci∗ in ti or soci∗ in ab or indir∗ in ti or indir∗ in ab or non-med∗i in ti or 
non-medi∗ in ab 
500803 
#5 #1 and #2 and #3 and #4 and (py>2002) 252 
#6 util∗ in ab or util∗ in ti 324129 
#7 #5 and #6  74 
 
Step 2 Exclusion based on abstract 
Reason Number* 
Studies did not fulfill selection criteria 37 
Non-Dutch study 48 
Modeling study 15 
Non-empirical study 15 
Multi-country study  5 
* total number higher than 74 due to several reasons possible 
 
Step 3 Exclusion based on full article  
Reference Topic Reason for removal 
Onrust (2008) [13] Visiting service for older widowed indi-
viduals  
no other economic evaluations 
Van den Hout (2008) [14] Treatments for sciatica from lumbar 
disc heriation 
no other trial-based economic 
evaluations 
Bulthuis (2008) [15] Exercise therapy by hospital discharged 
arthritis patients 
only Dutch economic evalua-
tions 
Zijlstra (2007) [16] Spa treatment for fibromyalgia no comparable studies 
Oude Voshaar (2006) [17] Tapering off benzodiazepines no other economic evaluations 
Korthals-de Bos (2006) [18] Treatments for carpal tunnel syndrome no other trial-based economic 
evaluations 
Steenstra (2006) [19] Back to work program for workers with 
low back pain 
only one other economic 
evaluation 
Van den Hout (2005) [20] Treatment programs for rheumatoid 
arthritis 
only foreign effect studies 
Van den Hout (2005) [21] Mobilisation techniques for adhesive 
capsulitis 
no other economic evaluations 
Korthals-de Bos (2004) [22] Interventions for lateral epicondylitis no other economic evaluations 
Van Dieten (2003) [23] Pharmaceutical treatments for reflex 
sympathetic dystrophy 
no other economic evaluations 
for this treatment 
Van den Hout (2003) [24] Radiotherapy for painful bone metasta-
ses 
no foreign economic evaluati-
ons 
Van den Hout (2003) [25] Multidisciplinary care for rheumatoid 
arthritis 
no other economic evaluations 
Korthals-de Bos (2003) [26] Treatments for neck pain not enough foreign economic 
evaluations 
 
Based on Dutch guidelines for costing research, a description of the necessary data 
was produced, whilst at the same time a search for suitable foreign studies was per-
formed [8]. The foreign studies have mainly been identified by looking at three sys-
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tematic reviews [27-29]. Furthermore, a systematic search was performed within 
the electronic databases Medline, PubMed and Econlit and in the most relevant 
journals, Spine and Pain. The following search strategy was used: low back pain 
[mesh] AND costs and cost analysis [mesh]; low back pain AND physical therapy 
[mesh] OR exercise* [tw] AND costs and cost analysis; low back pain AND pain clin-
ics [mesh] OR cognitive therapy [mesh] OR multidisciplinary treatm* [tw] AND clini-
cal trial [mesh]; low back pain AND pain clinics OR cognitive therapy AND costs and 
cost analysis OR effect* [tw]. All references were subsequently checked to identify 
additional studies. 
Making the predictions 
In the next step, the studies were assessed on their transferability to the Nether-
lands. This was carried out with the help of Welte’s model as described in the the-
ory section. The third general knock-out criterion states that the studies should pos-
sess an acceptable quality. The criteria list “Consensus on health economic criteria” 
(CHEC) was utilised to assess the methodological quality of the foreign studies [30]. 
By applying the general knock-out criteria, each treatment arm of a foreign study 
was separately examined to decide if the treatment arm could pass the criteria. In 
theory it is possible that one of the treatment arms passes the general knock-out 
criteria and that the other treatment arm not. All studies were assessed on the 
transferability of the data by two different reviewers. The corresponding author (SK) 
reviewed all articles and the other authors (AA, SE, and JS) divided the assessment 
of the studies among them. 
 
Table 3 Main structure of the model 
 
ICER = ΔC/ΔE 
ΔC = Ce - Cc 
ΔE = Ee–Ec 
E = Eqaly 
C = Ci + Ch + Csl 
Ch = (qgp * pgp) + (qit * pit) + (qth * pth) + (qopd * popd) + (qha * pha) + (qm * pm) 
Ce: total costs of experimental treatment Cc: total costs of control treatment 
Ci: total costs of intervention Ch: costs of health care consumption 
Csl: costs of sick leave Ee: effect of experimental treatment 
Ec: effect of control treatment p: price 
q: quantity qaly: quality adjusted life years  
gp: general practitioner it:  imaging techniques 
th: physiotherapist opd: outpatient department visit 
ha: hospital admission m:  medicine use 
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After the assessments, two different predictions were produced and both predic-
tions were based on the same model. The main structure of the model is given in 
Table 3. We distinguished three different costs groups, namely the intervention 
costs (Ci = qi * pi), sick leave (Csl) and other health care consumption (Ch). The costs 
of the multidisciplinary treatment itself were represented by Cmdt and of physio-
therapy by Cphysio. The effect of the treatments was expressed in quality adjusted life 
years (QALYs). 
To make the two predictions, data were extracted from the foreign studies. In the 
“all studies prediction” all foreign studies were used. In the “Welte’s model predic-
tion” all studies which passed the general and specific knock-out criteria and were 
therefore considered to be transferable, were used. The predictions were produced 
according to the Dutch guidelines for costing research [8]. 
Because of differences in relative prices between countries, it is not possible to 
transfer prices [4, 8]. As a result, all foreign prices were replaced by Dutch prices. All 
the available quantity data were pooled using the averages of all foreign studies and 
the Dutch prices were attached to these average quantities. In some cases the 
prices of rehabilitation centres were used to estimate the real costs. For all other 
costs the real prices of that specific treatment were used. All prices utilized, origi-
nating from 2003, can be found in the Dutch guideline for costing research [8]. The 
prices were adjusted to 2004 prices, because the Dutch study was based on 2004 
prices. The adjustment was carried out with the help of the consumer price index of 
the Netherlands [31]. Next to that, the effects of both the multidisciplinary treat-
ment and physiotherapy are calculated by looking at the change from baseline. 
Sensitivity analysis was performed to investigate the robustness of the predictions. 
For both predictions a high/low analysis was performed with only the highest and 
the lowest values used. This way, predictions with the lowest and the highest values 
of all parameters were available for the “all studies prediction” and the “Welte’s 
model prediction”. Furthermore, plots of the total costs were produced to identify if 
the predictions and the results of the Dutch study correspond with each other. 
In the last step, the two predictions were compared with a Dutch study on the same 
topic (Figure 1). 
Results 
After a thorough search for a suitable case, the chosen case study became subacute 
and chronic non-specific low back pain. The Dutch study that was chosen as refer-
ence case is the study of Van der Roer (2006). In this study the cost-effectiveness of 
physiotherapy was compared with a multidisciplinary treatment which included 
education, exercises and behavioural treatment [12]. 
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Figure 1 Flowchart of the method  
Transferability check: general knock-out criteria 
As a result of the search for foreign studies, a total of fourteen studies, from which 
the references and the characteristics are shown in Table 4, were identified. In all 
studies the cost-effectiveness or effectiveness of either physiotherapy or the mul-
tidisciplinary treatment was determined. The multidisciplinary treatment was de-
fined as the evaluated technology and physiotherapy as the comparator. A study 
was considered to be of low quality if it scored ten or lower out of the possible nine-
teen on the CHEC criteria list [30]. 
Seven studies, from which the references can be seen in Table 4, did not fulfil the 
general knock-out criteria. The studies of Cherkin et al. (2001) [32] and Wright, 
Lloyd-Davies, Williams et al. (2005) [33] did not fulfil the first and the third general 
knock-out criteria. In the studies of Karjalainen et al. (2003 + 2004) [34, 35], Molde 
Hagen, Eriksen and Ursin (2000) [36] and Molde Hagen, Grasdal and Eriksen (2003) 
[36] the right evaluated technology was not available. The studies of Cherkin, Deyo, 
Battie et al. (1998) [38], Klaber Moffet et al. (1999) [39] and Torstensen, Ljunggren, 
Meen et al. (1998) [40] had not enough quality and did not fulfil the third criterion. 
Use foreign quantities 
and Dutch prices 
Make “all studies pre-
diction” and perform 
sensitivity analysis 
Apply general knockout criteria 
Apply specific knockout 
criteria 
Use foreign quantities 
and Dutch prices 
Make “Welte’s model 
prediction” and per-
form sensitivity analy-
sis 
Compare the two predictions with each other and with the results of 
the Dutch reference study 
Search for articles 
Determination of the case 
Determinate which data are 
needed to make the predic-
tions with help of Oosten-
brink guideline  
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After passing the general knock-out criteria, the specific knock-out criteria were ap-
plied to the seven studies which passed the general knock-out criteria. 
 
Table 4 Characteristics of the studies on chronic non-specific low back pain 
 
Study 
Reason 
knock-out 
Country Intervention Perspective 
Time 
horizon 
Studies not passing knock-out criteria (group 1) 
Cherkin 
(2001)[32] 
Evaluator 
and quality 
USA 
Acupuncture, massage versus self-care 
education 
HMO/ health care 
12 
months 
Cherkin 
(1998) [38] 
Quality USA 
Physical therapy, chiropractic manipulation 
versus educational booklet 
Health care 
24 
months 
Karjalainen  
[34, 35] 
Evaluator Finland 
Mini-intervention, work site visit versus 
usual care 
Societal 
12 
months 
Klaber 
Moffet [39] 
Quality UK Exercise group versus usual care 
Societal and health 
care 
12 
months 
Molde 
Hagen  
[36, 37] 
Evaluator Norway Intervention group versus usual care Societal 
Costs 12 
months, 
effects 
36 
months 
Torstensen 
[40] 
Quality Norway 
Medical exercise therapy, conventional 
physiotherapy versus self exercise 
Social security 
office 
12 
months 
Wright [33] 
Evaluator 
and quality 
UK Usual care versus advice group Not clear 
2 
months 
Skouen [41] Perspective Norway 
Usual care, light multidisciplinary treatment 
versus extensive multidisciplinary treat-
ment 
Social security 
office 
26 
months 
Transferable studies (group 2) 
Brown [42] - USA Back school versus comparison Societal 
6 
months 
Fairbank  & 
Rivero-
Arias  [43, 
44]
 
- UK 
Spinal fusion surgery versus intensive reha-
bilitation 
Societal/health 
care 
24 
months 
Frost & 
Rivero-
Arias  [45, 
46] 
- UK Advice group versus physiotherapy group 
Societal and health 
care 
12 
months 
Kääpä [47] - Finland 
Multidisciplinary group rehabilitation ver-
sus individual physiotherapy 
Societal 
24 
months 
Skargren 
[48] 
- Sweden 
Chiropractic group versus physiotherapy 
group 
Societal 
12 
months 
UK BEAM 
[49, 50] 
- UK 
Exercise program, spinal manipulation pro-
gram, combined treatment versus usual 
care 
Health care 
12 
months 
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Transferability check: specific knock-out criteria 
The following factors were found to have a high relevance for this particular case: 
perspective, medical cost approach, productivity cost approach, and productivity 
and work-loss time. All studies in this case originate either from West European 
countries or from the United States. Nevertheless are within this case, chronic non-
specific low back pain, no large differences between these countries and the Neth-
erlands in patient population and in their main health care characteristics. The 
health care for patients with chronic low back pain is largely comparable between 
the study countries, therefore the practice variation and the technology availability 
is limited. Next to that, the Dutch prices were used for the calculations for the pre-
dictions. The relevant population characteristics for this case, incidence/prevalence; 
case-mix; health-status preference; acceptance, compliance and incentives to pa-
tients and productivity and work-loss time are with the exception of the last crite-
rion practically the same between the study countries. The health care and popula-
tion characteristics are therefore less important in this study, because of the simi-
larities between the countries [6]. 
Six of the seven studies were, partially, transferable to the Netherlands. The study 
of Skouen, Grasdal, Haldorsen et al. (2002) was not transferable because of differ-
ences in perspective, medical cost approach and because of problems with the data 
extraction [41]. 
The foreign studies were divided into two different groups. All studies that did not 
pass the general knock-out criteria or the specific knock-out criteria are in group 1. 
The second group comprises the studies that are considered to be transferable to 
the Netherlands. In the “all studies prediction” the results of group 1 are included 
and in the “Welte’s model prediction” the studies included in group 2 were used. 
Comparing predictions 
The results of the “all studies prediction”, the “Welte’s model prediction” and the 
Dutch reference study (Van der Roer, 2006) [12] were compared with each other. 
The results are presented in the Tables 5a and 5b. It is evident that the cost estima-
tions between the two predictions differ. In the “all studies prediction” the highest 
costs was for the physiotherapy group and this was caused by the high costs of sick 
leave. The average number of days of sick leave was 32.3 days in the physiotherapy 
group and in the other prediction this was 10.3 days. This high average in the 
physiotherapy group was caused by the study of Torstensen et al. [40], which re-
ported a high number of days of sick leave. As a result the average days of sick leave 
were high and this also influenced the total costs for the physiotherapy group sub-
stantially. In the “Welte’s model prediction” the highest total costs were for the 
multidisciplinary treatment group. The treatment costs of the multidisciplinary 
treatment were higher than the costs of physiotherapy in this prediction. This could 
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be explained by the intensity of the multidisciplinary treatment and the staff 
needed. 
 
Table 5a Recalculation of costs using Dutch prices 
 
 Cmdt* Cphysio* Csl* Ch* E 
International Studies 
Studies not passing knock-out criteria (group 1) 
Cherkin (2001) [32] 100 -  31  
Cherkin (1998) [38] - 162    
Karjalainen [34, 35] 154 -  294 0.88 
Klaber Moffet [39] - 185 1537 259 0.77 
Molde Hagen [36, 37] 154 -  12  
Torstensen [40] - 833 32508   
Wright [33] 251 -    
Skouen [41] 3670 -    
Transferable studies (group 2) 
Brown [42] 1257 - 2244   
Fairbank [43]& Rivero-Arias (2005)[44] 4442 -  132 0.48 
Frost [45]& Rivero-Arias (2006) [46] - 111 2698 87 0.74 
Kääpä [47] MDT 4402 - 2533   
     
Skargren [48] - 148  40  
UK BEAM [49, 50] - 218  141 0.64 
Predictions (base case) 
All studies prediction (group 1) MDT 1804 - 2388 216 0.68 
 
  
Welte’s model prediction (group 2) MDT 3367 - 2388 132 0.48 
 
Cmdt: costs multidisciplinary treatment Cphysio: costs physiotherapy 
C :   costs of sick leave sl C :      costs of health care consumptionh  
E:     effect of treatment * All prices in 2004 euros in the Netherlands 
 
 
The difference in effect, expressed in QALYs, between the two treatment options 
was rather large in the “Welte’s model prediction”, namely 0.21 QALYs in favour of 
the physiotherapeutic treatment. In the “all study prediction” the difference was 
0.04 in favour of the physiotherapy group. In the sensitivity analyses the differences 
in QALYs ranged from -0.26 to 0.11. 
In the Dutch study the multidisciplinary treatment was more effective, but also 
more expensive. The ICER was favourable for the multidisciplinary treatment, but 
this was mainly caused by a small difference in costs. 
In the next step the “all studies prediction” and the “Welte’s model prediction” 
were compared to the Dutch study. The difference in effect was high, namely -0.04 
for the “all studies prediction” and -0.21 for the “Welte’s model prediction” versus 
0.03 for the Dutch study. The cost differences in the predictions were larger than in 
physio - 463 3150   
physio - 303 9186 185 0.72 
physio - 351 2925 121 0.69 
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the Dutch results. For the “all studies prediction” the difference in costs was €-5266 
in favour of the multidisciplinary treatment and in the “Welte’s model prediction” 
the difference was €2490, whereas in the Dutch study it was €233. The main reason 
for the differences in costs between the predictions and the Dutch results was the 
higher costs of the multidisciplinary treatment in the predictions, whereas in the “all 
studies prediction” the costs of sick leave in the physiotherapy group were much 
higher. 
 
Table 5b Results of the two predictions and the Dutch study 
 
 Cmdt*
 
Cphysio*
 
Csl*
 
Ch*
 
ΔC E ΔE 
Predictions (base case)        
MDT 1804 - 2388 216 0.67 All studies prediction 
(group 1) physio - 303 9186 185 
-5266 
0.72 
-0.04 
MDT 3367 - 2388 132 0.48 Welte’s model prediction 
(group 2) physio - 351 2925 121 
2490 
0.69 
-0.21 
Sensitivity analysis        
high MDT 4442 - 2533 303 0.88 All studies  
prediction 
(group 1) 
 physio - 833 32508 356 
-26.419 
0.77 
0.11 
  low MDT 100 - 2244 76 0.48 
   physio - 111 1537 83 
   685 
0.64 
-0.16 
high MDT 4442 - 2533 132 0.48 Welte’s model  
prediction 
(group 2) 
 physio - 463 3150 171 
3323 
0.74 
-0.26 
low MDT 1257 - 2244 132 0.48 
 
 physio - 111 2698 83 
741 
0.64 
-0.16 
Dutch study         
Van der Roer [12] MDT 779 - 2806 307  
   physio - 312 2933 412 
233 
 
0.03 
Cmdt: costs multidisciplinary treatment Cphysio: costs physiotherapy 
C :   costs of sick leave sl C :      costs of health care consumptionh  
E:     effect of treatment * All prices in 2004 euros in the Netherlands 
 
 
The results in Figure 2 indicate the differences in total costs of the two treatment 
groups between the two predictions and the Dutch study. The highest correspon-
dence concerning the total costs for the multidisciplinary treatment is between the 
“all studies prediction” and the Dutch study. The total costs by the “Welte’s model 
prediction” are just outside the confidence interval of the Dutch study. For physio-
therapy, the results are different. In this case the total costs of the physiotherapy 
group by the “Welte’s model prediction” is almost comparable with the total costs 
in the Dutch study. The total costs by the “all studies prediction” are considerable 
higher than of the “Welte’s model prediction” and the Dutch study. 
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Figure 2 Plot of the total costs of the two predictions and the Dutch study 
Discussion 
Model of Welte 
The two predictions differ in both the costs and effect estimations of the multidisci-
plinary treatment and physiotherapy. Using Welte’s model yield better results for 
the cost prediction than when the foreign results are applied straightforward in the 
decision country, but the effectiveness prediction was less accurate. Because of the 
differences between the “all studies prediction” and the “Welte’s model predic-
tion”, it can be concluded that Welte’s model does influence the final results. The 
differences between the “all studies” and the “Welte’s model prediction” are 
caused by both the general and specific knock-out criteria. Seven studies were de-
leted by the general knock-out criteria and mainly by the third criterion (five out of 
seven studies) and one study by the specific knock-out criteria. The “Welte’s model 
prediction” was better in the costs estimations than the “all studies prediction”, 
because the estimation was more alike the Dutch results. However, the “all studies 
prediction” had the highest correspondence with the Dutch results concerning the 
effects estimation. 
In this case the general knock-out criteria had the most influence on the transfer-
ability of studies. It seems that if a study has a good methodological quality, the 
chance increases that the study is transferable. Another finding is that the model 
focuses mainly on the transferability of costs. 
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Difficulties encountered during the making of the predictions 
The first difficulty with making the current predictions was the diversity among the 
multidisciplinary treatments as described in the foreign studies. Therefore, some 
variation could be observed between the foreign studies and also between the for-
eign studies and the reference study. This difficulty will occur in almost every treat-
ment, which is caused by small differences in definition and practice variation be-
tween settings. 
The second difficulty occurred with the parameters ‘medicine’ and ‘imaging tech-
niques’. This difficulty is influenced by two problems. The first was the availability of 
the data on these two parameters and the second is the large practice variation be-
tween countries. In the available data it was unclear which drug was prescribed or 
which imaging technique was used. Therefore it was not possible to value these pa-
rameters at the right prices. Furthermore, it is known that large practice variations 
exist between countries, for example in drug prescriptions and standard of care. As 
a consequence, it was decided to exclude these parameters from the predictions. 
The third difficulty is that an additional test of the Welte criteria would have been 
comparing studies which pass versus those which do not pass the specific knock-out 
criteria, while excluding all those not passing the general knock-out criteria. A sup-
plementary comparison, in this study, could be solely with the studies that did not 
pass the specific knock-out criteria. This comparison indicates the importance of the 
specific knock-out criteria. However, by this case only one study did not pass these 
criteria. Therefore, the preferred comparison gave no or not much extra informa-
tion compared with the two current included predictions. 
Problems and recommendations concerning Welte’s model 
The main problem of Welte’s model, within this study, is that only the methodologi-
cal characteristics could be assessed without using extra information outside the 
articles. A large problem when transferring studies is the complexity of judging the 
health care and population characteristics. This extra information was not readily 
available. These characteristics and their corresponding factors are often not stated 
in the articles. The transferability literature [2-4] reveals that there is enough reason 
to believe that these factors influence the transferability of economic evaluations. 
However, in this case the health care and population characteristics were not ap-
plied, because of the high similarity between the study countries and the decision 
country. The population and the health care system corresponded sufficiently be-
tween the countries and therefore it was not considered necessary to correct these 
characteristics. 
The third general knock-out criterion states that the study should possess an ac-
ceptable quality, but it is not clear how the quality should be assessed by Welte [6]. 
Some common quality criteria for economic evaluations, like perspective and dis-
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count rate, are now used as transferability factors. However, it is known that be-
tween countries the guidelines for economic evaluations and the quality criteria 
differ. By stating general quality criteria this criterion will become clearer. 
Another problem of Welte’s model is the overlap between some of the factors, for 
instance between the factors ‘practice variation’ and ‘technology availability’ or 
‘medical cost approach’ and ‘absolute and relative prices’. As a consequence, it is 
harder to assess these factors. This makes it more difficult to use Welte’s model. 
The last problem deals with the lack of attention for the transferability of effects. 
Almost all specific knock-out criteria discuss the transferability of cost parameters. 
Only the criterion ‘health status preference’ focuses solely on the transferability of 
effects. However, some criteria have an influence on both costs and effects. Fur-
thermore, more attention should be given to how and with which instrument the 
effects are measured in a study, because this could influence the effect parameter. 
It is known from the literature that the valuation of health states and the instru-
ments used vary from country to country [51]. Therefore, this should be taken into 
account when transferring effect data to other countries. This could be a new factor 
in an improved version of Welte’s model. 
At this moment Welte’s model is mainly focused on the idea to assess the transfer-
ability of whole studies. In the case that a study as a whole is not transferable, it 
could be that a study section is still usable. Therefore, a second option to improve 
Welte’s model is to give more attention to the possibility to assess the transferabil-
ity of a section or sections of a study. By making it easier to assess the transferability 
of sections of studies more information might be available to calculate a prediction 
for the decision country. 
Implications of the results 
Welte et al. (2004) [6] stated that it is possible to transfer data to other settings, but 
the results were not compared with data from the decision country. The results of 
this study indicate that it is feasible to transfer data to the Netherlands. However, 
more case studies should be subjected to Welte’s model before a final conclusion 
can be drawn. In this study it was difficult to distinguish the effects of the general 
knock-out from the effects of the specific knock-out criteria. By this case, it is not 
clear why most studies passing the general knock-out criteria also passed the spe-
cific knock-out criteria. It is not clear whether this is due to this specific case. There-
fore, this needs to be clarified by applying Welte’s model to another case. The re-
sults of one case study, as presented in this article, is too limited to draw final con-
clusions on the functioning of Welte’s model. 
In addition, Welte’s model is not the only existing model to assess the transferability 
of economic evaluations. Boulenger et al. [3], Urdahl et al. [9] and Nixon et al. [10] 
are all published methods that by using a checklist try to assess the transferability of 
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studies. By the method of Boulenger et al. the answers to the questions lead to a 
transferability information score [3]. Nixon et al. have developed a method which is 
related to that of Boulenger. The economic evaluations are assessed with the help 
of a questionnaire that is based on the guidelines from BMJ [9]. However, it is hard 
to determine what these scores indicate, because no standards are available. The 
method of Urdahl et al. is developed for decision-analytic models to assess whether 
articles provide enough information to decision makers [9]. A combination of the 
Welte and Boulenger methods is suggested by Antoñanzas et al. [52]. The principle 
of general knock-out criteria is adopted from Welte, but the scoring system and the 
questions are based on Boulenger [52]. Nixon et al. is a supplementary paper on the 
method of Boulenger whereby some points of criticisms are discussed [53]. How-
ever, the interpretation of the scoring remains unclear. Given these recent devel-
opments, the next step will be to test the applicability of the methods of Boulenger 
[3, 53] and Antoñanzas [52]. 
To improve Welte’s model, additional research on the transferability of effects and 
on other transferability factors is needed. At the moment it is considered that ef-
fects are comparable in all countries, but more research is needed in this field [51]. 
Furthermore, in the literature [2-4] several transferability factors are listed, but it is 
yet unknown which factors have the most influence. When this is known, it will be 
easier to develop a new method for determining the transferability of economic 
evaluations. Welte’s model could then be used as a template. Welte’s model 
worked reasonably well in this case, but improvements are necessary to make the 
model easier to use. 
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Abstract 
Background: For at least two decades there has been an intense debate on whether 
and how to include the value of lost productivity in economic evaluations. This de-
bate is often reflected in pharmacoeconomic guidelines, which have been devel-
oped to indicate the methods and requirements for the design, execution and re-
porting of economic evaluations in a particular country. 
Objective: To examine what various national pharmacoeconomic guidelines rec-
ommend regarding the identification, measurement and valuation of lost productiv-
ity. 
Methods: First, the theoretical framework on how lost productivity can be identi-
fied, measured, and valued is described. Second, a summary sheet has been used to 
identify various pharmacoeconomic guidelines recommendations regarding the 
value of lost productivity. 
Results: Twenty-two of the thirty guidelines identified recommend performing eco-
nomic evaluations using the societal perspective. However, even if the societal per-
spective is recommended it is not always clear how the value of lost productivity 
should be taken into account. Most guidelines recommend including the costs of 
absenteeism from paid and/or unpaid work. In addition, although no agreement 
exists on how lost productivity should be valued, none of the guidelines recom-
mended using the US panel approach for the valuation of lost productivity. 
Discussion: The different recommendations hinder international transferability of 
the value of lost productivity. This difficulty is mainly caused by different recom-
mendations regarding identification and valuation. These differences result from 
the debate and lack of consensus on including the value of lost productivity losses in 
economic evaluations. It will become easier to transfer data across jurisdictions if all 
data are reported transparently. 
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Introduction 
During the last two decades there has been disagreement about whether or not the 
value of lost productivity should be included in economic evaluations and, if so, how 
these losses should be valued [1]. One of the areas of discussion is the methodology 
that has been advocated for the valuation of these losses [1-3]. The US panel states 
that lost productivity influences the health-related quality of life of people and that 
consequently the losses should be assessed in the quality-adjusted life-year (QALY) 
[4], while others state that the lost productivity should be incorporated in the costs 
[1, 2]. Furthermore, the adequate identification of the value of lost productivity, 
especially in the short-term, is still an under-researched area. Nevertheless, the im-
portance of correct identification should not be underestimated. Due to the differ-
ent ideas about identification, measurement and valuation, pharmacoeconomic 
guidelines differ in their recommendations on this topic [1]. 
Several countries have developed pharmacoeconomic guidelines [5].National guide-
lines are developed primarily to indicate the requirements for the design, execution 
and reporting of the results of economic evaluations in a specific country [5, 6]. 
These guidelines are utilized to improve the quality of economic evaluations by en-
couraging good research practice. This should lead to greater standardization, which 
in turn should increase the comparability of studies and may increase the generalis-
ability of results [6]. Results are considered generalisable if they can be applied to 
other settings without any adjustments [7]. 
However, country-specific guidelines may stipulate, in addition to the use and pres-
entation of local data, the use of specific methods as well. As a result, the require-
ments stated in various national guidelines are not always comparable [7, 8]. More-
over, there are several factors that may cause variations in the cost-effectiveness 
estimates of health technologies from place to place, and these will hinder the 
transferability of economic evaluations [7, 9]. Data are considered transferable if 
they can be adapted to apply to other settings or jurisdictions [7]. Therefore, it can 
be considered reasonable for national guidelines to stipulate that economic evalua-
tions be relevant to the local context as well [7, 9]. 
One of the possible differences between national guidelines is the recommended 
perspective. When performing an economic evaluation, an explicit statement 
should be given regarding the perspective from which costs and effects are esti-
mated. There is a strong theoretical preference that economic evaluations should 
be performed from a societal perspective, but many studies are carried out from 
more narrow perspectives. This theoretical preference for the societal perspective is 
related to the foundations of economic evaluations in welfare economics, which is 
concerned with the welfare of society [2, 10]. Therefore an overall assessment of 
the efficiency of a technology should consider the various consequences from a lar-
ger societal perspective and not just for the individuals who are directly involved 
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[2]. As a consequence, when economic evaluations are carried out from the societal 
perspective, the value of lost productivity should be included in the analysis, which 
might not be the case when using a more narrow perspective [2, 3]. See Figure 1, 
section A ‘Perspective’. 
 
 
 
Figure 1 Valuing health related lost productivity 
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The terms ‘production cost’, ‘productivity cost’, ‘production loss’ and ‘productivity 
loss’ all refer to the monetary valuation of a reduction in productivity. In this re-
spect, Brouwer et al. (1997) define productivity costs as “costs associated with 
working time lost and replacement costs due to illness, disability and death of pro-
ductive persons, both paid and unpaid” [11]. In contrast, the term ‘value of lost 
production’ refers to both the monetary valuation and valuation in effects of a re-
duction in productivity. Therefore, in this article we will use the term ‘productivity 
costs’ and ‘(value of) lost productivity’ accordingly. 
Considering the fact that productivity reduction related to disease can be substan-
tial - for example the costs of lost productivity can exceed health care costs - clear 
guidance is needed on how to value lost productivity in economic evaluations [12]. 
When various national guidelines have different recommendations regarding the 
identification, measurement and valuation of lost productivity, it hinders or makes it 
harder to transfer data across jurisdictions. In this study thirty national pharma-
coeconomic guidelines were compared with each other regarding lost productivity, 
and a summary sheet was used to identify the recommendations in the various 
guidelines. Accordingly, the objective of this study is to examine what the existing 
national pharmacoeconomic guidelines recommend regarding the identification, 
measurement and valuation of lost productivity. 
First, the theoretical background of the value of lost productivity is described in 
three steps within the theoretical framework. Second, the methodology section de-
scribes the requirements of the national pharmacoeconomic guidelines and the de-
velopment of the summary sheet. In the results section the different recommenda-
tions of the guidelines regarding lost productivity are summarized, and in the dis-
cussion, conclusions are drawn from the results. 
Theoretical framework 
Identification 
In section B ‘Identification’, of Figure 1, the alternative operationalisations of lost 
productivity can be found. The value of lost productivity is often divided into paid 
working time, non-paid working time and leisure time [1, 13, 14]. Lost productivity 
in paid working time can occur in the following situations: being present at work but 
working at a reduced capacity due to health problems (presenteeism); or being ab-
sent from work (absenteeism). In absenteeism the distinction can be made between 
short- and long-term absenteeism, where short term absenteeism is being defined 
as absenteeism shorter than six weeks. In addition, mortality and permanent dis-
ability can be categorised as a kind of long-term absenteeism. Moreover, transitions 
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between these types of reduced productivity are possible [1, 14-16]. This division is 
also useful for the identification of lost productivity in non-paid labour. 
One of the most common phenomena of lost productivity is presenteeism in paid 
working time. There are two situations in which presenteeism may occur: when 
health problems do not result in absenteeism yet do result in lost productivity, and 
when health problems cause not only absenteeism but also lost productivity during 
a period of time before and after absence. Furthermore, compensation mechanisms 
may limit productivity loss, but it is unclear how effective these mechanisms are. 
When an employee makes up for lost work by working overtime on his return to the 
workplace, this may lead to additional costs for the employer or to reduced leisure 
time. If the lost work is compensated for during normal working hours, this may be 
carried out during breaks or by working at a faster pace [17]. 
Identifying the value of lost productivity, in effect using a single effect measure cov-
ering both the consequences of morbidity and mortality, obviously leads to using 
the QALY-concept. Of course, the point of controversy - whether lost productivity 
should be valued in monetary or effect terms - influences not only the identification, 
but also the measurement and the valuation of lost productivity [18-20]. 
Measurement in costs and QALYs 
Section C ‘Measurement, of Figure 1, shows that, depending on the identification 
phase, lost productivity can be measured in various ways. The most appropriate 
method for measuring the value of lost productivity is still under discussion mainly 
because the adequate measurement of short term lost productivity is still an under-
researched area [1, 2]. For paid labour, data from human resource departments 
may be unreliable and data on presenteeism and compensation mechanisms are 
mostly not taken into account due to difficulties with measuring these types of lost 
productivity. Therefore, many economic evaluations utilize patient-reported meas-
ures of lost productivity [5]. Most of these instruments assess the reduction in input 
due to absenteeism or presenteeism. The problem is that hardly any of the existing 
instruments have been completely validated. Furthermore, large differences in pro-
ductivity costs can be found depending on the instrument used [21, 22]. At the 
moment, questionnaires for patient-reported data are an acceptable method for 
measuring the value of lost productivity; taking into account that, in our opinion, 
the ideal instrument would capture absenteeism, presenteeism and compensation 
mechanisms. The use of questionnaire for patient-reported lost productivity is the 
only method for measuring lost productivity in non-paid labour [5]. 
The measurement of the QALY may be realised through randomized controlled tri-
als, observational data, uncontrolled experiments and expert opinion, possibly in 
combination with life expectancy data. The QALY weights must be preference-
based, interval-scaled and measured or transformed into an interval scale in which 
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the score of 0.0 is the reference point for ‘death’ and the score of 1.0 indicates ‘per-
fect health’ [4]. 
 
Table 1 Methods for valuing lost productivity in economic evaluations 
 
 Human Capital  
Approach (HCA) 
Friction Cost Method 
(FCM) 
US Panel Approach 
Valuation valuation in monetary way valuation in QALY 
Calculation - multiply gross wage  
by number of sick days 
(2); estimation of value 
of all lost production (3) 
- value productivity 
losses of individuals with 
ill health during friction 
period (2) 
- productivity losses 
should be valued 
through a generic pref-
erence-based measure 
(2) 
Description - value changes in the 
amount of time indi-
viduals are able to allo-
cate to paid work as a 
result of illness (2)  
value of productivity 
loss due to illness (2) 
- friction period: time it 
takes to replace and to 
train a replacement 
worker (2) 
- assumes that everyone 
can be replaced (5) 
- compensation mecha-
nisms included in the 
valuation of changes in 
paid working time (2) 
- time costs associated 
with morbidity as-
sessed within QALY and 
placed in denominator 
(23) 
- separation of impact 
of illness on quality of 
life from effects on role 
function is difficult (23)  
Background - based on neoclassical 
theory (2) 
- assumed that there is 
no unemployment (3) 
- developed as alterna-
tive for perceived rough-
ness of  human capital 
approach (2) 
- assumes that absentee-
ism reduces the effective 
labour time less than 
proportionally (24) 
- monetary valuation of 
productivity losses 
results in double count-
ing if QALY is used as 
measure of benefit (2) 
Advantage - relatively easy method 
to apply (2, 5) 
- useful for estimating 
productivity losses for 
unpaid labour (3) 
- more realistic method 
for quantifying produc-
tion losses (3) 
- no double-counting of 
productivity losses 
possible, because these 
losses are included in 
QALY (2) 
Disadvantage - overestimation of 
costs because compen-
sation mechanisms are 
not taken into account 
(25) 
- overestimation of 
costs by death or dis-
ablement  (5) 
- indirect costs for peo-
ple outside labour force 
not included (24) 
- rejects the key tenets of 
conventional micro-
economic theory (2); no 
foundation in economic 
theory (24) 
- no overall agreement 
with assumptions used 
(23, 24) 
 
- underestimation of 
costs, because net 
wages and not the 
gross wages will be 
incorporated (2); not 
always link between 
inability to work and 
loss of income (2) 
- not in agreement with 
common view on the 
inclusion of costs (5) 
 
- measure of potential 
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Valuation in costs and QALYs 
Section D ‘Valuation’, of Figure 1, indicates again that lost productivity can be val-
ued in costs and in QALYs. The most frequently used methods for valuing productiv-
ity costs in paid labour are the Human Capital Approach (HCA) and the Friction Cost 
Method (FCM) [2]. The US panel approach is the only method for the valuation of 
lost productivity in the QALY. An overview of methods is given in Table 1. 
Previous research has indicated that the application of either the HCA or the FCM 
leads to different estimates of productivity losses. For example, in a Canadian study 
by Goeree et al. (1999) it was calculated that the HCA resulted in a sixty-nine times 
higher estimation than the FCM [26]. In an article by Koopmanschap et al. (2005) 
several ratios ranging from 1.03 to 3273 were presented, in which the FCM showed 
lower estimations of the productivity losses than did the HCA (1). Furthermore, 
Hutubessy et al. (1999) calculated the annual productivity losses of back pain in the 
Netherlands using both the HCA and FCM. The total costs for the HCA, including 
both absenteeism and disability, were US $1545 million, while the FCM showed 
costs of US $842 million [27]. 
Although it can be considered as a kind of absenteeism, the valuation of lost pro-
ductivity due to mortality is not often taken into account when calculating lost pro-
ductivity [2, 28]. Furthermore, in most economic evaluations little attention is paid 
to presenteeism. However, for some chronic diseases, the value of lost productivity 
due to presenteeism may be comparable or even higher than the costs of absentee-
ism and direct health care costs combined [17, 22, 28]. Presenteeism is most fre-
quently mentioned and incorporated by advocates of the FCM [1, 2]. Compensation 
mechanisms may lead to lower estimates of lost productivity. Therefore, in order to 
calculate possible cost reductions, one should calculate the costs of compensation 
and the gains of the reduced value of the lost productivity. The net result of these 
two parts will be the reduction in costs as a result of compensation [17]. 
When using the societal perspective, lost productivity in non-paid labour becomes 
relevant [2]. Two monetary methods for valuing lost productivity in non-paid labour 
are the opportunity costs method and the shadow price method. In using the op-
portunity costs method, the input, or the sacrificed time is valued, and with the 
shadow price method the output, i.e. the commodities not produced, are valued. 
Shadow prices are often calculated using the wages of household help or by the 
gross wage-rate of individuals with paid work that closely matches the unpaid work 
[2, 28]. Opportunity costs are calculated using the value of forgone leisure time or 
the net wage that would be obtained by an individual if they were in paid employ-
ment [2]. 
According to the US panel, the effects of a health intervention on lost productivity 
are incorporated in the denominator of the cost-effectiveness ratio [4]. Therefore, 
the full impact of morbidity changes should be valued using preference-weighted 
measures of health-related quality of life [4, 20]. Furthermore, changes in life expec-
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tancy are also included in the denominator and should therefore not be included in 
the numerator [4]. However, using the US panel approach, time spent by the patient 
in receiving treatment should be captured in the numerator by calculating the op-
portunity costs [4, 20]. 
Methods 
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
presents an overview of pharmacoeconomic guidelines around the world on their 
website (www.ispor.org/PEguidelines/index.asp). These pharmacoeconomic guide-
lines may be government regulatory documents, publications, or suggested guid-
ance or best practices for conducting and using economic evaluations in health care 
and reimbursement decisions. On this webpage a comparative table of thirty-two 
main features of the guidelines is presented. Furthermore, the hyperlinks or the 
publication references are given for all guidelines [29]. Only the pharmacoeconomic 
guidelines that are included on this section of the ISPOR website were used for 
comparison. Consequently, most guidelines could be found using the hyperlinks or 
references given in the list of country-specific pharmacoeconomic guidelines on the 
ISPOR website. Pharmacoeconomic guidelines that could not be obtained from the 
website (Denmark, Finland and Switzerland) were retrieved by contacting research-
ers located in the respective countries. The guidelines of Brazil, China, Cuba, the 
Slovak Republic and South Korea were available only in their national language. In 
order to retrieve all relevant information from these guidelines, native or fluent 
speakers were contacted to obtain translations (see acknowledgements). 
We developed a sheet to systematically summarize the recommendations related to 
the perspective and identifying, measuring and valuing lost productivity as de-
scribed in the guidelines. The summary sheet contained questions about lost pro-
ductivity resulting from absenteeism, as well as lost productivity related to unpaid 
labour, compensation mechanisms and presenteeism. The summary sheet made it 
possible to include other remarks related to the value of lost productivity. Each 
pharmacoeconomic guideline was evaluated using this summary sheet, which will 
be made available online in the supplementary files. 
Results 
In total thirty national pharmacoeconomic guidelines on how to perform economic 
evaluations were identified for the comparison. The vast majority of the guidelines, 
twenty-three, were guidelines from European and Northern American countries. 
The other seven guidelines were developed in Asia, Oceania or Latin America. The 
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guideline of China is not included in the comparison, because the researchers con-
tacted did not respond to our request for retrieving the required information from 
the guideline. 
Perspective of economic evaluations 
In total twenty-two of the thirty received guidelines recommended performing eco-
nomic evaluations using the societal perspective [30-51]. However, the societal per-
spective is not the preferred perspective in all these guidelines. The guidelines that 
do not require or suggest the societal perspective often recommend performing 
economic evaluations from the perspective of the payer or of the health care sector 
[52-58]. As a result, these guidelines do not mention how the value of lost produc-
tivity should be included and were therefore not included in the rest of the com-
parison. However, even if the societal perspective is recommended, it is not always 
clear if and how lost productivity should be taken into account. For example, the 
Cuban guideline indicates that the societal perspective should be used, but the 
guideline does not indicate which costs should be identified, measured or valued. 
However, aspects of different costing methods, as for example the HCA, are de-
tailed in the Appendix [40]. In addition, several guidelines that recommend using 
the societal perspective state that productivity losses should not be included in the 
base-case analysis [30, 31, 33, 43, 44, 48, 50]. Other guidelines state that the value 
of lost productivity should be taken into account only if it is relevant to the study 
question or if it is clear that productivity has changed due to the disease or treat-
ment [32, 37, 42, 44, 45]. Figure 2 shows the process of handling and comparing the 
pharmacoeconomic guidelines as carried out in study. 
 
 
 
Figure 2 Processing of pharmacoeconomic guidelines 
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Identification, measurement and valuation of lost productivity 
As indicated in the theoretical framework, lost productivity can be related to paid 
and non-paid working time and to leisure time. The distinctions of different types of 
lost productivity are not clear in all guidelines. For example, in the Austrian guide-
line no clear difference is made between short- and long-term absenteeism. Most 
guidelines, as can be seen in Table 2, recommend including the costs of absentee-
ism. However, some guidelines simply state that the value of lost productivity 
should be included in the analysis, but do not indicate which costs should be identi-
fied. 
 
Table 2 Identification of lost productivity in paid work as indicated in guidelines 
 
 absenteeism presenteeism mortality compensation permanent 
functional 
impairment 
unclear ** 
 short long unclear*      
Austria (51)   X  X X   
Brazil (38)   X  X    
Cuba (40)        X 
Denmark (32)        X 
Finland (43)   X      
         
France (34)   X      
Germany (41)   X X     
Hungary (50) X X       
Ireland (45)        X 
Italy (35)   X      
         
Netherlands (36) X X   X    
Norway (31) X X   X  X  
Poland (44)        X 
Portugal (37)        X 
Russia (49)   X X X    
         
Slovak Republic (42)   X      
South Korea (30) X X   X    
Spain (47)        X 
Sweden (39)        X 
Switzerland (48)   X X X    
Thailand (46)   X  X    
USA (33) X X       
* Unclear what kind of absenteeism should be included 
** Unclear whether lost productivity should be included 
 
The results shown in Table 2 make clear that, for example, the inclusion of presen-
teeism and compensation mechanisms is not consistently recommended. However, 
when looking at the recommendations in detail, several similarities can be identi-
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fied. The Hungarian, Dutch, Norwegian, South Korean and American guidelines all 
recommend including short- and long-term absenteeism. The guidelines of Austria, 
Brazil, Finland, France, Germany, Italy, Russia, the Slovak Republic, Switzerland and 
Thailand state that absenteeism should be included, but do not distinguish between 
short- and long-term absenteeism. Presenteeism should be included according to 
the guidelines of Germany, Russia and Switzerland. In addition, the guidelines of 
Austria, Brazil, the Netherlands, Norway, Russia, South Korea, Switzerland and Thai-
land recommend including mortality. Only the Austrian guidelines state that com-
pensation mechanisms should be taken into account. The Norwegian guidelines are 
the only one that state that permanent functional impairment should be included as 
part of lost productivity. In the guidelines of Cuba, Denmark, Ireland, Poland, Portu-
gal, Spain and Sweden it is not clear how lost productivity should be taken into ac-
count. Finnish guidelines indicate that not only should the value of lost productivity 
of paid work be identified and valued, but also the value of leisure time lost because 
of disease. However, it is not clearly stated how this should be done. The Russian 
guidelines recommend including the costs of absence from work for family mem-
bers and other caregivers. 
 
Table 3 Measurement and valuation of lost productivity   
 
 HCA FCM US panel Other method Not clear 
Austria (51) X X    
Brazil (38) X     
Cuba (40)     X 
Denmark (32) X X    
Finland (43)     X 
      
France (34)  X    
Germany (41) X     
Hungary (50) X     
Ireland (45)     X 
Italy (35) X     
      
Netherlands (36)  X    
Norway (31) X X    
Poland (44) X     
Portugal (37)     X 
Russia (49)    X  
      
Slovak Republic (42) X     
South Korea (30)    X  
Spain (47)     X 
Sweden (39) X     
Switzerland (48)     X 
Thailand (46) X     
USA  (33)  X    
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Measuring and valuing lost productivity 
As previously indicated, not all guidelines recommending the societal perspective 
indicate which productivity losses should be included, and this is also the case for 
the valuation of lost productivity. In the majority of the guidelines there is no de-
scription of how lost productivity should be measured and valued; this is clarified 
only in the national guidelines from France and South Korea. The French guidelines 
recommend using surveys to measure lost productivity in economic evaluations. 
Furthermore, the guidelines of South Korea state that the methodology for measur-
ing the value of lost productivity depends on the cost items and the availability of 
data. However, questionnaires, databases, surveys and expenditure diaries are all 
mentioned as suitable methods. 
The results in Table 3 show that eleven guidelines recommend following the HCA, 
six guidelines recommend the FCM, and that none of the guidelines recommend the 
US panel approach. However, in six guidelines it is not clear which method should 
be used to value lost productivity. 
Although, for example, the Swiss guidelines do not indicate how lost productivity 
should be measured and valued, lost productivity is referred to as indirect costs. The 
Russian and the South Korean guidelines make no mention of the three methods for 
measuring and valuing productivity losses, but recommend using opportunity costs. 
The remaining guidelines recommending a societal perspective do not indicate how 
lost productivity should be valued. 
Discussion 
Our study, examining what various national pharmacoeconomic guidelines recom-
mend regarding the identification, measurement and valuation of lost productivity, 
clearly indicated differences between the guidelines. It can be concluded that the 
different recommendations hinder the transferability of data regarding the value of 
lost productivity. This is mainly caused by differences in the recommendations in 
the several guidelines. These differences reflect the debate on including the value of 
lost productivity in economic evaluations. As a result, no consensus exists among 
researchers, which has led to different recommendations. 
To begin with, not all guidelines recommend using the societal perspective. The use 
of the societal perspective is the most comprehensive option when performing eco-
nomic evaluations, thus taking the value of lost productivity into account. However, 
the decision for the perspective is not the only choice which is relevant for the value 
of lost productivity. Although the Canadian guidelines recommend using the per-
spective of the health care sector, the guidelines include recommendations on the 
identification and valuation of lost productivity [54]. Furthermore, some guidelines 
recommending the societal perspective do not specify how the value of lost produc-
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tivity should be included in economic evaluations, while other guidelines have in-
cluded only a few lines or a small paragraph on the subject. As a result, the informa-
tion is often not clear or incomplete, leaving substantial degrees of freedom on ex-
actly how to calculate the value of lost productivity. 
Significant differences exist between the guidelines on all aspects of identification, 
measurement and valuation of lost productivity. As recommendations on the identi-
fication of lost productivity differ greatly, this influences the final estimation. In ad-
dition, the different recommendations regarding the valuation of productivity losses 
will also result in different estimates. Previous research, as indicated in the theo-
retical framework, has shown that the application of the Human Capital Approach 
or of the Friction Cost Method leads to different estimates of productivity losses [1, 
26, 27]. Furthermore, our results indicate that problems could arise concerning the 
transferability of data when the guidelines are complied with in all economic 
evaluations. As a consequence, if there is disagreement between the guidelines on 
the identification and valuation of lost productivity, it will be difficult to use these 
results in other countries. In addition, none of the twenty-two guidelines recom-
mending a societal perspective indicate that the US panel approach should be used 
for valuing lost productivity. Therefore it can be concluded that in all guidelines lost 
productivity should be valued in costs and not in effects – despite concerns that the 
monetary valuation of lost productivity might result in double counting. 
For several reasons, only national pharmacoeconomic guidelines that are listed on 
the ISPOR website are included in this comparison, meaning that material from 
textbooks and national submission guidelines were not included. The national 
pharmacoeconomic guidelines have been developed by national governments, rep-
resentative organisations of governments or professional organisations, but they 
could also be publications or documents with suggested guidance or best practices. 
We decided to use the list of guidelines of the ISPOR website, because we expect 
that national pharmacoeconomic guidelines are more often utilized as guidance for 
economic evaluations than are textbooks, particularly for the purpose of policy de-
cision making. Furthermore, national guidelines indicate more clearly the view-
points of researchers or decision making bodies on how economic evaluations 
should be performed within a specific jurisdiction than do textbooks that are usually 
written by researchers without any jurisdiction in mind. 
Due to the diversity of the recommendations in the guidelines, a lot of variation ex-
ists in the design of economic evaluations. The differences are mainly caused by 
some guidelines' instruction to use specific methods or to perform economic 
evaluations from a limited and only locally relevant perspective. Therefore, it is ad-
visable that some recommendations in the pharmacoeconomic guidelines become 
more standardised and comparable. This can be achieved by developing interna-
tional pharmacoeconomic guidelines. Such international guidelines could address 
the minimum requirements or minimum package that an economic evaluation 
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should fulfil, and of course national, additional requirements could guide adjust-
ments to specific jurisdictions. One topic that certainly needs to be addressed is the 
inclusion of the value of lost productivity in economic evaluations. An unequivocal 
description of how to include the value of lost productivity will benefit the transfer-
ability of these data. However, it will be difficult to develop such a guideline, be-
cause of the different viewpoints on the requirements of a good economic evalu-
ation. This hampers the possibility, for the time being, of reaching consensus on a 
European or international level. Nevertheless, several international organisations, 
like ISPOR and the European network for Health Technology Assessment 
(EUnetHTA), are paying attention to developing unequivocal methods and guide-
lines for economic evaluations. 
Furthermore, more attention should be paid to other suitable solutions for reducing 
the differences between pharmacoeconomic guidelines. One option is to identify 
the fundamental differences regarding the identification, measurement and valu-
ation of lost productivity. However, it will be necessary for all guidelines that rec-
ommend the societal perspective to indicate clearly if and how lost productivity 
should be identified, measured and valued. This can be seen as the first step toward 
finding possible solutions for dealing with these differences. By identifying the fun-
damental differences it might be easier to come to consensus regarding some key 
points. Of course, more insight regarding the alternative methods available is war-
ranted through research on the validity and reliability of measuring and valuing lost 
productivity. 
In addition, it would be easier to decide if data from other jurisdictions can be trans-
ferred if all the data are reported transparently. This would help to assess if data 
can be used elsewhere. Therefore, it would be advisable to have minimum require-
ments for the reporting of economic evaluations in journals. These requirements 
should indicate which parts of economic evaluations should be described in detail. 
At the same time, there should be some focus on developing general guidelines, and 
more research should be carried out regarding the fundamental differences in rec-
ommendations on including the value of lost productivity. 
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Appendix 
SECTION A  General 
Country: 
Year: 
Source or web link:  
Sponsored or authorized by: 
 
SECTION B Perspective 
Perspective:       mentioned, namely;                      not mentioned, most likely….. 
o Societal    
o Government        
o Health care sector 
o Health care insurer 
o Health care provider 
o Employer 
o Employee 
o Others, namely ……..                  
 
SECTION C Identification 
Lost productivity identified:    mentioned, namely;        
 not mentioned, most likely….. 
o Short term absenteeism (< 6 weeks) from paid work 
o Long term absenteeism (> 12 weeks) from paid work 
o Short term absenteeism (< 6 weeks) from unpaid work 
o Long term absenteeism (> 12 weeks) from unpaid work 
o Absenteeism due to mortality 
o Short term presenteeism (< 6 weeks) from paid work 
o Long term presenteeism (> 12 weeks) from paid work 
o Short term presenteeism (< 6 weeks) from unpaid work 
o Long term presenteeism (> 12 weeks) from unpaid work 
o Compensation, by…… 
o Other, ….. 
o Not relevant due to perspective 
o Unknown                                                                                                        
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SECTION D Measurement 
Measurement of lost productivity:   mentioned, namely;         
 not mentioned, most likely…… 
o Questionnaire 
o Databases 
o Survey 
o Expenditure Diary Approach  
o Other, namely ….  
o Unknown 
 
SECTION E Valuation 
Methods of valuation of lost productivity and what kind of lost productivity: 
o Human Capital Approach, by ….  
o Friction Cost Method, by…. 
o US Panel Approach, by…. 
o Opportunity Costs, by …  
o Shadow Prices, by… 
o Other, namely…. 
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Abstract  
From previous research it has become clear that the recommendations regarding 
lost productivity differ among national pharmacoeconomic guidelines. These differ-
ences in guidance result in different ways of identifying, measuring and valuing lost 
productivity, with consequent difficulties when comparing lost productivity esti-
mates. From a transferability point of view, the question arises whether differences 
in lost productivity are the result of using different calculation methods (methodo-
logical differences) or are due to cultural differences. The objective of this study is 
to investigate whether the country of residence has a significant influence on the 
quantity of lost productivity, correcting for confounding factors that might differ 
between countries, while keeping the methodology the same. This question is in-
vestigated by means of an online questionnaire that was filled out by respondents 
in four European countries. In addition to questions regarding lost productivity, the 
questionnaire contained questions about patient characteristics, disability insur-
ance, disease characteristics, quality of life and labour characteristics as these fac-
tors could also influence lost productivity. The data were analysed by regression 
analyses, in which different components of lost productivity were the main outcome 
measure and correction took place for the other variables as between-country dif-
ferences could be caused by differences on the other variables. The results showed 
that country sometimes has a significant influence on lost productivity and that 
other variables also influence lost productivity. Significant differences between 
countries were found on the variables ‘being absent in the last three months’ and 
‘quality of work on the last working day’. However, countries did not differ in terms 
of the variables ‘number of days absent’, ‘quantity of work on the last working day’ 
and ‘overall presenteeism on the last working day’. In addition, other included vari-
ables also have a statistically significant influence on lost productivity. As a result, 
transferring lost productivity data between countries is not advisable, it is prefer-
able to measure lost productivity in the country of interest.   
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Introduction 
National pharmacoeconomic guidelines are used in a growing number of jurisdic-
tions to support the decision making process in the health care sector. These guide-
lines are used to support the design and execution of economic evaluations [1]. 
However, carrying out economic evaluations is time consuming and costly. In addi-
tion, it requires the availability of trained researchers so that it may not be possible 
to perform all the evaluations in one’s own jurisdiction. As a result most technolo-
gies are evaluated in only a limited number of jurisdictions. Nevertheless, there is 
pressure for decision makers to transfer economic evaluations data across jurisdic-
tions. This raises the question of whether the results of economic evaluations car-
ried out in other jurisdictions can be transferred without causing problems [2-6]. 
Due to differences between for instance health care systems, epidemiology of dis-
eases, clinical practice patterns and relative prices, the results of economic evalua-
tions do not travel well across jurisdictions. The ISPOR Task Force on Transferability 
indicates that data are generalisable if they can be applied without adjustments to 
other settings. Data are transferable if they can be adapted to apply to other set-
tings than the study country [7]. 
So far, the majority of research regarding the transferability of cost-effectiveness 
data has focused solely on the transferability of health care costs. Costs are consid-
ered as the outcome where quantities and prices are multiplied. Quantities are of-
ten considered transferable, but the prices of the elements not. Prices are fre-
quently mentioned transferability factors, but on the other hand resource use or 
quantities is considered as a less important transferability factor as it is mentioned 
less frequently [8]. Until now no research has been carried out on the transferability 
of lost productivity. It is already clear that the prices of one day of lost productivity 
need to be adapted as salaries differ between individuals and countries, but it is not 
clear whether the quantities – number of days - are dependent on country when 
comparing people with the same disease. Nevertheless, the costs of lost production 
related to disease can be substantial, to such a degree that these costs can exceed 
the total costs of health care, for instance in rheumatoid arthritis [9]. It has already 
been discussed earlier that whether or not lost productivity should be included in 
economic evaluations is point of debate. As a result national pharmacoeconomic 
guidelines have different recommendations regarding the identification, measure-
ment and valuation of lost productivity. These different recommendations can re-
sult in large differences in lost productivity estimations, which hinder the transfer-
ability [10]. Moreover, most transferability research is hampered by differences in 
methodological guidance between countries. These differences in guidance result in 
different ways of identifying, measuring and valuing lost productivity, with conse-
quent difficulties when comparing cost and quantity estimates. The question arises 
whether differences in lost productivity are the result of using different calculation 
Chapter 5 
 70 
methods (methodological differences) or are due to other differences between 
countries [10]. 
Lost productivity usually develops when someone becomes ill and is therefore no 
longer able to work or is less productive. Lost productivity consists of two compo-
nents, namely absenteeism (sickness absence or days off work) and presenteeism 
(reduced performance at work) [11]. In this article, only the absenteeism of people 
with a paid job are taken into account and as a consequence absenteeism related to 
full disability not. However, the development of lost productivity is also influenced 
by other factors, such as disease characteristics, quality of life and job characteris-
tics. Each factor can affect the development of lost productivity differently, but the 
influence of the country in which someone is living when corrected for other factors 
like disease severity has not yet been explored. When lost productivity data differ 
significantly across countries, the transferability of the data is comprised across 
countries. The influence of the country can only be investigated by measuring lost 
productivity using the same method by a comparable patient population at the 
same time in different countries as disease and disease severity could have a larger 
influence on lost productivity than country. In addition, the influence of other fac-
tors that influence los productivity should be taken into account as ignoring their 
influence could lead to an overestimation of the influence of country. When after 
correction for the influence of other factors, still significant differences between 
countries can be found the conclusion can be drawn that the transferability of lost 
productivity data is seriously hindered. This study tries to explain which factors in-
fluence lost productivity and whether this differs between countries.  
Theoretical framework 
In addition to the possible influence of country, several other factors can be identi-
fied that influence the development of lost productivity. Figure 1 shows the factors 
described in the literature that influence the development and magnitude of lost 
productivity. 
Lost productivity (P), with absenteeism and presenteeism as its components, is a 
complex phenomenon that can be caused by physical and psychosocial complaints 
which in turn may be influenced by a range of factors [12]. In addition, lost produc-
tivity can be seen related to the severity of the disease (B) [13, 14]. The factors re-
garding disease characteristics are made specific for the fact that our study concen-
trates on rheumatic disorders. Therefore, in the case of rheumatic disorders it is 
described that especially the factors disease duration and pain are related disease 
severity and to lost productivity [15]. It is known that different levels of impairment 
(B) and different levels of quality of life (E) will lead to different levels of observed 
productivity (P) [16]. When the impairment (B) is limited, individuals may choose to 
stay at work, even though they are likely to be less productive (presenteeism), and 
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as the disease progresses, the impairment may increase and the individual may de-
cide to stay at home (absenteeism). When the individual is recovering, there is a 
point at which the person decides to return to work, while being not fully produc-
tive yet [16]. Other research has indicated that, apart from disease and quality of 
life, absence is influenced by factors at a personal level (A), work related factors (C) 
and societal factors, like the insurance system (D) [11]. 
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Figure 1 Factors that influence lost productivity 
 
There is also an indication that the type of work influences lost productivity and that 
country (F) influences the duration of absence from work (P) [17]. The relation be-
tween work-related factors (C) and reduced performance at work (P) has also been 
the subject of study. It has been found that low job control, high time demands, 
high physical and output demands, and high psychosocial load are associated with 
reduced performance at work [11]. Costs of absenteeism (P) are calculated by mul-
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tiplying the number of absent days with the gross earnings, and this should reflect 
the costs of lost productivity when individuals are absent from work. The actual 
costs of lost productivity could be different, as the absence is compensated for (C) 
which is the case for both short-term and long-term absence. The work could be 
covered by others or the work is carried out by the individual when returning to 
work and these compensating mechanisms (C) influence the estimation of the costs 
of lost productivity (P). Therefore, taking compensating mechanisms into account 
will lead to lower estimations of the costs of lost productivity [18]. In addition, 
country (F) also influence the risk of being work disabled (C) [17]. The moment 
when people become less productive or absent probably depends on a combination 
of factors such as the type of work (C), type of illness (B), specific health domains 
affected (E), whether absence has consequences for the productivity of other work-
ers and the financial consequences of being absent or less productive to the individ-
ual [14]. Some conflicting results can be found about the influence of gender (A). 
The research of Laaksonen et al. (2008) in several countries indicated that women 
have more absenteeism than men. Differences in the working conditions of men 
and women may provide some explanation for the gender differences, because 
some working conditions have been associated with lost productivity [13]. However, 
according to Gimeno et al. (2004) in most countries men have a higher average of 
absent days than do women [19]. Furthermore, the total societal costs of a disease, 
including the costs of lost productivity, are not only influenced by patient (A) and 
disease characteristics (B and E), but also by international differences in medical 
practice, differences in financing and organising of health care and differences in 
social security systems (D) [17]. It was also found that the percentage of people on 
sick leave in southern European is lower than the EU average. One explanation 
could be that in many countries (F) the income (C) on absence is limited resulting in 
a loss of income. Furthermore, it seems that in countries where people are fully 
paid in cases of temporary disability, a higher rate of absence can be observed [19]. 
At the moment, it is not clear to what extent and in what direction these different 
factors besides country have an influence on lost productivity, but this question will 
be explored in this study. Therefore, taking the other factors into account will result 
in a more accurate estimation of the influence of country. Only when other factors 
are taken into account the between-country differences within the sample for ex-
ample the variables age or quality of life will be corrected for. The objective of this 
study was to investigate whether the country of residence has a significant influ-
ence on the quantity of lost productivity, correcting for all possible confounding 
factors that might differ between countries, while keeping the methodology the 
same. This leads to the following research question: To what extent is lost produc-
tivity that is absenteeism and presenteeism, influenced by differences in country - 
corrected for quality of life, disease characteristics, patient characteristics, labour 
characteristics and insurance? 
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Methods 
Population and procedures  
To investigate if lost productivity differs between countries, data about individual 
lost productivity were needed. The data were collected by the research organisation 
TNS NIPO, but the development of the questionnaire and the data-analyses were 
carried out by the authors. This organisation sent potential eligible respondents in a 
homogenous disease state an email with a link to an online questionnaire. People 
were eligible for this research if they had a rheumatic disorder – either self-reported 
or confirmed by a medical doctor - and were between twenty and sixty-five years of 
age. The choice was made to include only working age-respondents with the same 
disease to be sure that the populations in the countries were comparable. Previous 
research has indicated that musculoskeletal diseases, which have a high prevalence, 
have a high impact on worker participation and productivity. Therefore, a significant 
part of the societal costs of reduced productivity are caused by musculoskeletal 
problems [20]. It is also known that the costs due to lost productivity are an impor-
tant part of the total costs of rheumatic disorders; e.g. in rheumatoid arthritis, the 
costs of lost productivity account for 25% to 71% of the total costs of the disease [9, 
17]. The age limit was intended to increase the chance that the respondents were 
employed and neither still studying nor already retired. All potential respondents 
were members of the patient panels of TNS NIPO, and all these people were willing 
to fill out questionnaires for a small reward. TNS NIPO gave some points for any 
questionnaire the respondents filled out and the collected points can be converted 
into gift vouchers. The respondents could fill the questionnaire out at whatever 
time suited them the best, but there was a restriction of a total of two hundred re-
spondents per country resulting in a total of eight hundred respondents. From each 
country a reasonable number of respondents with lost productivity were needed. 
Enough respondents should have a paid job as only then lost productivity can occur. 
Since twenty different variables were included in the analyses, a total of two hun-
dred respondents per country were needed. The questionnaire was sent to respon-
dents in four European countries namely France, Germany, the Netherlands and the 
United Kingdom (UK), being England and Wales. The Netherlands was chosen be-
cause it is the country in which the study was initiated. The other three countries 
were selected because the maximum prices of pharmaceuticals in the Netherlands 
are determined by taking the average of the prices in four so-called reference coun-
tries. These four reference countries are decreed in the law Pharmaceutical Prices in 
which four neighbouring countries are selected, namely Belgium, Germany, France 
and United Kingdom [21]. Consequently, these four countries are of interest for the 
Netherlands. Nevertheless, Belgium was not included in this study as, given the ex-
isting panels, it was not possible to include two hundred respondents from both 
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language regions within Belgium, being Wallonia and Flanders. Respondents from 
both regions were needed as the legislation and other variables differ between the 
two regions.   
Measures  
The questionnaire was developed to measure the different constructs as displayed 
in Figure 1. Whenever available, existing validated questionnaires or specific parts 
of such questionnaires were utilized. Health-related quality of life was measured 
using the EQ-5D, which is a generic instrument used in economic evaluations to cal-
culate the utility for the health state described with the instrument. The answers on 
the EQ-5D were utilized to calculate utilities using the British, Dutch, French and 
German value sets [22, 23]. Patient characteristics, job characteristics and lost pro-
ductivity were measured using the Productivity and Disease Questionnaire (PRO-
DISQ), which is a modular questionnaire that has been developed for measuring lost 
productivity for people with paid labour. Presenteeism, as one of the components 
of lost productivity, was operationalized by making a distinction between the qual-
ity and quantity of work on the last working day of the respondent. Respondents 
could indicate how well and how much work was carried out on their last working 
day on a ten point scale. Presenteeism occurred whenever the respondent scored 
lower than ten on the scale. These two presenteeism scales were also combined to 
create an overall presenteeism score [24, 25]. One of the components of the job 
characteristics as given in Figure 1 is job control, which consists of job demand and 
decision latitude. Job demand is related to an aggregate of psychological stressors 
affecting work, which are often task pressures. Decision latitude can be described as 
the individual’s potential job-related decision making. The questions on job control 
were converted into two scales, namely job demand and decision latitude [26]. The 
questions about the severity of the rheumatic disorder were selected from the 
Dutch-Arthritis Impact Measurement Scales-2 (Dutch-AIMS2), which is an instru-
ment for assessing the health status of patients with rheumatic disorders. The re-
spondents have to indicate the disease severity and impact and pain of the disease 
in the last twelve months. One of the questions from this questionnaire allowed for 
calculating the number of years a respondent had had a rheumatic disorder [27]. 
The overall general health questions were the first questions from the European 
Health Status Module; part of the European Health Interview Survey [28]. Overall 
general health was measured using two questions, namely general health and ex-
perienced health. General health could be scored ranging from very good to very 
poor and the experienced health was scored on a scale ranging from 0 to 100. Coun-
tries can differ in two ways, namely in system characteristics and cultural differ-
ences. Differences in system characteristics cause differences in the procedures and 
financial consequences concerning temporary absenteeism and the regulations on 
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disability and disability insurance between countries [19]. Because there is no inter-
national questionnaire about disability insurance for individuals, these questions 
were formulated in consultation with experts in the field, after identifying the in-
formation needed. Cultural differences could result in different attitudes towards 
labour and sickness, which can cause differences of opinion on absenteeism and 
disability. Something else that has to be kept in mind is that the included variables 
are also correlated with each other, not only the variables which are related to the 
same box of characteristics, but also variables that belong to other characteristics, 
for example, severity of disease and health-related quality of life. Original versions 
of the questionnaires were utilized when they existed in the relevant language, for 
instance the EQ-5D, and translated from Dutch by professional translators when 
necessary, for instance for PRODISQ.  
Statistical analyses 
To begin with, dummy variables were created for categorical variables with more 
than two categories. Furthermore, the whole dataset was checked for missing data. 
Simple imputation methods were used for missing data on the variables ‘educa-
tional level’ and on the ‘percentage of disability’. The missing data were imputed by 
utilizing the answers on related variables, for example whether or not the respon-
dents were partly disabled. After the simple imputation, multiple imputations with 
five imputations were performed for the variables ‘hours per week of paid labour’ 
and ‘number of days of paid work’. The results pooled across the five imputed data-
sets are reported. To investigate whether variables were significantly different be-
tween the four countries, one-way ANOVA tests were done for continuous variables 
and χ
2
-tests were done for categorical variables. Only respondents having a paid job 
were included in the analyses. Logistic regression analysis was performed to exam-
ine the influence of country on being absent or not in the last three months and on 
presenteeism during the last working day. Linear regression analysis was carried out 
to investigate the influence of country on the number of absent days in the last 
three months. In each of these analyses, other variables that could also influence 
lost productivity according to the theoretical framework were included as additional 
predictor variables. Multicollinearity was checked by calculating the variance infla-
tion factor (VIF) for each predictor variable. When VIF was above 10, different 
strategies were used to lower the multicollinearity. Categorical variables with two 
levels were recoded in 1 versus -1, and categorical variables with more than two 
levels were recoded using an orthogonal coding scheme [29]. Continuous variables 
were centred (the total average was deducted from the score of each individual 
respondent). These strategies were sufficient to decrease the VIF value below the 
critical value. At first all relevant predictor variables were included in the analysis 
model. Except for the dummy variables representing the four countries, non-
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significant predictor variables were deleted from the model step by step, each time 
removing the least significant one, but with a p-value > 0.10. The p-values for the 
results pooled across multiple imputations were employed. Dummy variables were 
deleted if, for continuous outcomes, the F-Change, or for binary outcomes, the like-
lihood ratio of the model with versus the model without dummy variables was not 
significant. For the reduced model containing only significant predictors, the effects 
of country were examined for significance. All statistical analyses were performed 
using SPSS 17.  
Results 
Characteristics of the respondents 
In Table 1 the characteristics of the whole sample and of the respondents with a 
paid job in the four included countries are reported. The average age of the respon-
dents in the four countries is between forty-eight and fifty-two and, for respondents 
with a paid job, between forty-five and fifty years. UK respondents are significantly 
older than respondents in France and Germany. In addition, the average duration of 
a rheumatic disorder is between ten and fourteen years, and this average in the 
Netherlands is significantly higher than in the UK. In the Netherlands and UK the 
percentage of respondents who consider their own health to be very good or good 
is higher than in France and Germany. However, the utility scores are significantly 
lower in the UK than in Germany and France, which conflicts with the UK respon-
dents’ own perception of their health. The higher utility scores in Germany are not 
in line with the results, which show that the German respondents are significantly 
more restricted due to their rheumatic disorder than are respondents in the Nether-
lands and in the UK. The statistically different valuations on the variables between 
countries by the respondents of their own health, restricted by disease, utility and 
experienced health do not result in a significant difference between the countries 
on the variable impact of the rheumatic disorder. Significant differences can be 
identified in the percentage of respondents who still have paid work. In the Nether-
lands about seventy-five percent of the respondents work, but the average number 
of contract hours is the lowest among the four countries. Furthermore, the charac-
teristics of the respondents with a paid job indicate that these are on average 
younger, and have a better health; they are less restricted by the rheumatic disor-
der and its duration is shorter.  
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Absenteeism in the last three months  
The four countries differ in terms of being absent or not from work in the last three 
months. As can be seen in Table 2, respondents living in the UK have been absent 
significantly less often than respondents in the Netherlands, but the numbers of 
people being absent in France and Germany were also lower than in the Nether-
lands, although not significantly. Furthermore, the results show that persons who 
are seriously restricted or somewhat restricted are more often absent than persons 
who are not restricted. The B-value of 1.85 and the Odds Ratio of 6.25 indicate that 
as the variable increases, the odds of being absent in the last three months in-
crease. The number of contract hours is also related to being absent. Respondents 
with a higher number of contract hours have a higher rate of being absent. How-
ever, older respondents and respondents with a fixed contract are absent less often. 
This model has a R
2
 of 0.17, meaning that 17% of ‘being absent’ is explained by the 
model.   
 
Table 2 Results of logistic regression on being absent in the last three months 
 
 B Std. error Odds Ratio 
Country 
 UK versus the Netherlands -.85 .31 .43*
 France versus the Netherlands -.50 .29 .61
 Germany versus the Netherlands -.18 .27 .84
Patient characteristics 
 Age (years) -.03 .01 .97*
Disease characteristics 
 Seriously restricted versus not restricted 1.85 .40 6.25**
 Somewhat restricted versus not restricted .82 .30 2.27*
Labour characteristics  
 Temporary contract (1: yes, 2: no) -.76 .37 .47*
 Number of contract hours (hours) .03 .01 1.03*
Quality of life  
 General Health (1: very good- 5 very poor) .26 .15 1.30
Note R
2
 = 0.17 (Nagelkerke) Model χ
2
 = 69.28. * p > .05. ** p > .001 
Number of days absent in the last three months  
The F-Change of the model with versus the model without country is not significant 
(F-Change = 0.742), indicating that the model without country, Model 2, is more 
appropriate. Hence country has no significant influence on the number of days of 
being absent in the last three months. From the B-value in the first regression 
model it can be seen that the variables seriously restricted and whether work will be 
compensated by others lead to respectively 24 and 10 days more absent. The ad-
justed R
2
 is 0.282 for Model 2, without dummy variables for country, implying that 
28.2% of the ‘number of days absent’ is explained by this model (see Table 3). 
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Table 3 Results of linear regression analysis on number of days absent   
 
Model 1 B Std. Error Beta
Country  
 UK versus the Netherlands 0.21 5.81 .00
 France versus the Netherlands 5.40 4.98 .09
 Germany versus the Netherlands 5.66 4.39 .10
Patient characteristics 
 Gender (1: male, 2: female) -7.88 3.45 -.15*
Disease characteristics 
 Years of rheumatic disorder  -0.46 0.19 -.17*
 Seriously restricted versus not restricted 24.61 6.82 .43**
 Somewhat restricted versus not restricted  8.13 5.69 .16
Labour characteristics  
 Shift work (1: yes, 2: no) -8.07 4.04 -15*
 Decision latitude (1: never- 4: always) -2.64 1.58 -.12
 Compensation by others (0: no, 1: yes) 10.58 4.08 0.19*
Disability insurance  
 Requested disability insurance (1: yes, 2: no) 8.23 4.32 0.14
Quality of life  
 General health (1: very good- 5: very poor) 4.31 2.49 0.14
Note R
2
 = .331; adj. R
2
 = .279 for Model 1; * p > .05; ** p  > .001 
Model 2 B Std. Error Beta
Patient characteristics  
 Gender (1: male, 2: female) -7.83 3.42 -.15*
Disease severity  
 Years of rheumatic disorder (continue) -.47 .18 -.17*
 Seriously restricted versus not restricted 24.05 6.71 .42**
 Somewhat restricted versus not restricted 7.05 5.57 .14
Labour characteristics  
 Shift work (1: yes, 2: no) -8.53 3.64 -.16*
 Decision latitude (1: never- 4: always) -2.26 1.51 -.10*
 Compensation by others (0: no, 1: yes) 9.62 4.02 .17*
Disability insurance 
 Requested disability insurance (1: yes, 2: no) 8.85 4.25 .15*
Quality of life  
 General health (1: very good- 5: very poor) 5.62 2.28 .18*
Note R
2
 = .321; adj. R
2
 = .282 for Model 2;  * p > .05; ** p  > .001 
 
The variables gender, years of rheumatic disorder, the degree to which the respon-
dent is restricted by the disease, shift work,  decision latitude in the work of the re-
spondent, compensation by others, disability insurance requested or not and, gen-
eral health explain the number of working days lost due absenteeism. On average, 
men, respondents who never requested disability insurance and who work in shift 
have a higher number of days absent than do women and respondents who re-
quested disability insurance with regular working hours. The variable ‘years of 
rheumatic disorder’ has a negative correlation with the dependent variable, mean-
ing that a respondent who has suffered from a rheumatic disorder for many years 
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has a lower number of absent days than does a respondent who has had a rheu-
matic disorder for fewer years. Furthermore, high decision latitude, meaning one 
has considerable freedom to make one’s own decisions in their work, is associated 
with a smaller number of days being absent. The degree of restriction due to the 
rheumatic disorder is positively correlated with the dependent variable. Respon-
dents who are seriously restricted are on average a larger number of days absent 
than are respondents who are not restricted because of their rheumatic disorder. 
Having poor general health or respondents whose work was taken over by others 
when absent, being compensated by others, had a higher number of absent days.   
Presenteeism   
Overall presenteeism is significantly influenced by a number of variables. The model 
has a R
2
 of 0.16, thus 16% of the overall presenteeism is explained by the model. 
Poor general health significantly increases the possibility of presenteeism at work. 
In addition, a larger number of contract hours and a high job demand are also posi-
tively related to presenteeism. However, having a rheumatic disorder for a higher 
number of years have a negative relation with regard to presenteeism, meaning a 
decreased possibility of presenteeism at work. When a respondent has high deci-
sion latitude at work this also decreases the possibility of presenteeism. Regarding 
overall presenteeism the variable country has no statistical significant influence.  
In addition, having a temporary contract, a larger number of contract hours and a 
high job demand are also positively related to presenteeism. Being partly disabled 
and having a rheumatic disorder for a higher number of years have a negative rela-
tion with regard to presenteeism, meaning a decreased possibility of presenteeism 
at work. When a respondent has high decision latitude at work this also decreases 
the possibility of presenteeism. Regarding overall presenteeism the variable country 
has no statistical significant influence.  
The statistical model explains 17% of the quality-related presenteeism. The possibil-
ity of quality-related presenteeism is significantly higher in France and Germany in 
comparison with the Netherlands. In Germany in particular, there is a higher chance 
that the quality of the work is lower than normal in comparison with the Nether-
lands. Furthermore, the number of contract hours increases the possibility of pre-
senteeism. However, some other variables are negatively related to the occurrence 
of presenteeism. A better experienced health, a high utility score and high decision 
latitude decrease the possibility that the quality of work on the last working day was 
lower than on a normal working day.  
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Table 4 Results of logistic regression analyses on presenteeism 
 
Presenteeism B Std. Error Odds Ratio
Disease characteristics 
 Years of rheumatic disorder  -.03 .01 .97*
Labour characteristics  
 Temporary contract (1: yes, 2: no) .57 .30 1.77
 Decision latitude (1: never- 4: always) -.27 .09 .76*
 Job demand (1: never- 4: always) .31 .17 1.36*
 Number of contract hours (hours) .03 .01 1.03*
Disability Insurance  
 Partly disabled (1: yes, 2: no) -.88 .35 .41*
Quality of life  
 Experienced health (0: worst possible – 100: best possible)  -.01 .01 .99
 General health (1: very good- 5: very poor) .58 .15 1.79**
Note R
2  
= .16 (Nagelkerke) Model χ
2 
= 69.71 * p > .05, ** p > .001 
 
Quality presenteeism  B St. Error Odds Ratio
Country  
 UK versus the Netherlands .22 .28 1.24
 France versus the Netherlands .65 .26 1.91*
 Germany versus the Netherlands  1.04 .27 2.84**
Patient characteristics  
 Age (years) -.02 .01 .98
Labour characteristics  
 Relation with colleagues (0: very bad – 10 very good) -.08 .05 .92
 Decision latitude (1: never- 4: always) -.19 .09 .83*
 Number of contract hours (hours) .03 .01 1.03*
Disability Insurance  
 Partly disabled (1: yes, 2: no) -.57 .33 .57
Quality of life  
 Experienced health(0: worst possible – 100: best possible)   -.02 .01 .98*
 Utility EQ-5D (0: worst-1: best possible health) -1.02 .49 .36*
Note R
2 
 = .17 (Nagelkerke) Model χ
2 
 = 70.90 * p .> .05, ** p > .001 
 
Quantity presenteeism B St. Error Odds Ratio
Disease characteristics 
 Impact disorder (0: worst possible – 100: best possible) .01 .00 1.01*
 Years of rheumatic disorder  -.03 .01 1.03*
Labour characteristics  
 Temporary contract (1: yes, 2: no) .82 .31 2.27*
 Number of contract hours (hours) .03 .01 1.03*
Disability insurance  
 Partly disabled (1: yes, 2: no) -1.21 .33 .30**
Quality of life  
 General health (0: worst possible – 100: best possible) .59 .13 1.80**
Note R
2  
= .15 (Nagelkerke) Model χ
2  
= 60.85  * p .> .05, ** p > .001 
 
Being partly disabled leads to a reduction in the quantity of work on the last work-
ing day. The country someone is living in does not have a significant influence on 
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the quantitative dimension of presenteeism. When the rheumatic disorder has a 
high impact on the respondent’s life, and when having the disorder for a longer pe-
riod, then presenteeism is less likely in the sense that less work is done. Further-
more, having poor general health, a fixed contract, and a high number of contract 
hours result in a lower quantity of work, thus less work was carried out on the last 
working day than on average. The R
2
 of the model is 0.15, meaning that 15% of the 
quantitative dimension of presenteeism is explained by the statistical model.   
Discussion 
The results show that country has a statistically significant influence on the depend-
ent lost productivity variables. In these respondents with rheumatic disorders, not 
only disease characteristics and quality of life, but also the country of residence in-
fluence lost productivity. Significant differences can be found between the Nether-
lands, the UK, France and Germany on the variables ‘being absent in the last three 
months’ and ‘quality of work on the last working day’. Between-country differences 
could not be found in terms of the variables ‘number of days absent’, ‘overall pre-
senteeism’ and ‘quantity of work on the last working day’. Therefore, it can be con-
cluded that country has a significant influence on lost productivity, even when cor-
rected for the other variables that influence lost productivity. Therefore, we con-
clude that due to the significant differences between countries it is not advisable to 
transfer lost productivity data between countries without adaptation, because the 
transferability of the data is hindered by significant differences between countries. 
It was already clear that wages are different across countries, but our results indi-
cate that the quantity part of lost productivity also differ across countries, even af-
ter correcting for other between-country differences. However, the results did not 
clarify if the between-country differences are the consequence of differences in sys-
tem characteristics or of cultural differences. 
In addition to country some other variables included in the theoretical framework 
had a statistically significant influence on lost productivity. Although these variables 
all belong to characteristics presented in this framework, which variables are signifi-
cant differs slightly among the dependent variables. However, several variables are 
statistically significant in more than one analysis. The variables ‘severity of the dis-
ease’ and ‘shift work’ are statistically significant related to absenteeism, but not for 
presenteeism. In addition, the variables experienced health, utilities, partly dis-
abled, and relation with colleagues are significant for presenteeism, but not for ab-
senteeism. However, a number of variables are included in the statistical models for 
both absenteeism and presenteeism related outcome measures. Age, years of 
rheumatic disorder, decision latitude, temporary contract and number of contract 
hours are all statistically significant in both absenteeism and presenteeism related 
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models. The overall results indicate that a variety of variables have a statistically 
significant influence on lost productivity. Furthermore, only a part of the lost pro-
ductivity could be explained by the models. The statistical models explained the lost 
productivity from 15% up to 28%. This indicates that other factors which were not 
included in the theoretical model and the analyses also influence lost productivity. It 
could be that compensation mechanisms have an influence on presenteeism. This 
was not taken into account in this study as the compensation mechanisms were 
only included for absenteeism.  In addition, coping strategies of the respondents 
with their disease could probably also influence the development and magnitude of 
lost productivity. Respondents with more adequate coping strategies could have 
less lost productivity. However, it is unclear which other factors have a significant 
influence on either the development or magnitude of lost productivity.  
The theoretical framework indicates, according to the literature which variables 
have influence on lost productivity. In particular, the influence of country on lost 
productivity was not clear and this influence was investigated in this study. The 
variables included in the theoretical framework as described in the introduction can 
be seen as a starting point, because all elements have a statistical influence on lost 
productivity. In addition, in international studies, country should be included in the 
theoretical framework, because country has been found to have a statistically sig-
nificant influence on some components of lost productivity.  
Limitations of the study 
The study presented in this article has several limitations, mostly related to the 
study sample. In order to create a sample with a homogeneous disease state, the 
sample included only respondents with a rheumatic disorder. Including patients 
from a more general population with different disease states might have introduced 
bias. However, it is not clear if the diagnosis of the rheumatic disorder was con-
firmed by a medical doctor for all respondents. It is possible that respondents with 
only a self-reported rheumatic disorder were included in the sample. The choice for 
rheumatic disorders could also have influenced the results in other ways, because it 
is possible that the diagnoses and acceptance of rheumatic disorders differ across 
countries. The results presented are therefore applicable only to this population and 
our findings need to be confirmed in other disease areas.  
Moreover, respondents living in four European countries were included. In the Uni-
ted Kingdom, France and Germany a total of two hundred respondents per country 
and in the Netherlands two hundred thirty respondents were included in the sam-
ple, resulting in a total of eight hundred thirty respondents. In the analyses only re-
spondents with a paid job were included, resulting in a total of five hundred thirty-
nine eligible respondents. This number of respondents was large enough to perform 
all statistical analyses and to identify statistically significant differences. The number 
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of countries however, was limited to four Western European countries, but these 
countries are considered to be the reference countries for the pharmaceutical 
prices for the Netherlands. However, it is not clear if the results found in this study 
can be generalised to other Western European countries. The social security system 
is well developed in these four countries, which is not always the case in other 
countries. As a consequence, our results are probably also not useful for other Euro-
pean countries or countries in other continents due to differences in labour markets 
and due to differences between social security systems. Furthermore, including 
more countries will explain whether between countries differences in lost produc-
tivity can be found which will strengthen the evidence.  
In addition, the study questionnaire was developed using existing validated ques-
tionnaires or specific parts of such questionnaires. Unfortunately, no international 
questionnaires about disability insurance for individual respondents were available. 
As a consequence, the questions concerning disability insurance had to be specially 
formulated for this research and these remain not validated. But more important, 
other influential factors that so far remain unknown are not part of the theoretical 
model. The variables included in the framework were relevant and sometimes sta-
tistically significant, but the R
2
 of the models was at the most 0.28, meaning that a 
substantial proportion of the variability in our data cannot be explained. Subse-
quently, except from the possible influence of compensation mechanisms by pre-
senteeism and coping strategies, other factors that influence lost productivity have, 
to our knowledge, not been identified.  
Implications of results 
The results show that country has a relevant and statistically significant influence on 
lost productivity. This means that between-country differences can be found re-
garding lost productivity. Therefore, lost productivity data are not comparable 
across countries; this hinders the transferability of lost productivity data. Therefore, 
data regarding lost productivity and productivity costs cannot be transferred be-
tween jurisdictions without problems. It is not yet clear how the lost productivity 
data can be adapted in a valid manner. However, only respondents with a rheu-
matic disorder from only four European countries were included. It is advisable to 
carry out more research to investigate whether lost productivity – especially quan-
tity - differs between other countries and among other patient groups.  
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Abstract  
Background: Within the framework of economic evaluations, the transferability of 
utility scores between jurisdictions remains unclear. The EQ-5D is a generic instru-
ment for measuring health-related quality of life in economic evaluations; which can 
be used for comparing utility scores across countries. At present, the EQ-5D has 
several national value sets or tariffs. Nevertheless, utility estimates from foreign 
studies are often used directly for cost effectiveness estimates, without adapting by 
applying the appropriate national value set. It is unclear if this practice is advisable, 
due to dissimilarities between the national value sets. 
Objective: To examine the effects of differences in national EQ-5D value sets on ab-
solute and marginal utilities of health states, and determine to what degree these 
differences can be explained by methodological factors. 
Methods: First, the relative importance of the EQ-5D domains for the utility esti-
mates was compared across the 15 value sets. Second, two hypothetical health 
states for a hypothetical depressed patient and a hypothetical pain patient (21232 
and 33321) were selected for additional analysis, by comparing the utilities as 
scored by the value sets. The marginal influence of a one level deterioration in a 
domain of these health states on the utility estimate was then determined. Third, 
the differences between the value sets were examined in more detail by using mul-
tilevel analysis to examine the role of methodological differences in the valuation 
studies. 
Results: Differences can be perceived between the national value sets of the EQ-5D 
in the preferences for the domains. The utilities of the two hypothetical health 
states show that the value sets differ substantially. Furthermore, the differences 
between the marginal values of the deteriorations are large, which can be explained 
partly by the type of valuation method. Other methodological differences also influ-
ence the value sets. 
Conclusion: All results indicate that the differences between the EQ-5D value sets 
are considerable and should not be ignored. The differences can largely be ex-
plained by methodological differences in the valuation studies. The remaining dif-
ferences may reflect cultural dissimilarities between countries. Therefore, further 
research should focus on investigating the transferability of utilities across countries 
or to agree on a standard to perform valuation studies. For the time being, transfer-
ring utilities from one country to another without any adjustment is not advisable. 
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Introduction 
Healthcare providers and payers are increasingly interested in using the results of 
economic evaluations to guide their decision making [1]. Due to the rapid interna-
tional spread of new health technologies, there is a need to undertake, or at least 
interpret, economic evaluations on the international level [2]. Nevertheless, findings 
of economic evaluations may not be easily transferable due to differences in health-
care and economic systems, although data are transferable if they can be adapted 
to apply to other settings or jurisdictions [3 ,4]. In the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) task force report on transfer-
ability, [4] different national guidelines were reviewed with regard to their state-
ments about transferability. All guidelines recognized that several factors influence 
the transferability of economic evaluations. It is generally assumed that costs always 
differ between countries and therefore, cost data should always be adjusted [3,5]. 
Most guidelines recognized the differences in clinical effectiveness parameters be-
tween countries and that these can lead to differences in economic evaluations. It is 
suggested that country-specific estimates of baseline risk should be used, but that 
treatment effects from clinical trials might be more transferable. However, there is 
no unanimous agreement on this. Moreover, less than 40% of the guidelines make 
any recommendations about the transferability of health-state valuations or utility 
estimates across countries. The remaining guidelines recommend using value sets 
from the country of interest [5]. 
The EQ-5D, a generic instrument for measuring health-related quality of life (HR-
QOL) in economic evaluations, was developed by the EuroQol group in order to 
compare utilities across countries [6]. At the moment, seventeen national EQ-5D 
value sets (previously referred to as tariffs) are available, but only a limited number 
of comparisons have been carried out. The conclusions of these comparisons were 
that the dissimilarities could be caused by cultural dissimilarities, differences in 
population preferences or dissimilarities in the methodology used in the valuation 
process [6-9]. Levy et al. [10] indicated that when measurement methods to derive 
utilities are replicated exactly, only small differences across jurisdictions emerge in 
absolute utility scores. Since methodological differences were eliminated, the re-
maining differences were probably cultural differences. 
Nevertheless, utilities from foreign studies are often used directly, without adapting 
the results by using the appropriate national value set. Due to dissimilarities be-
tween the value sets it is unclear if this practice is advisable. However, the interpre-
tation of dissimilarities between the utility values of health states is complex. More 
clarity is needed on the influence of methodological dissimilarities, before the cul-
tural differences can be determined. Therefore, the objective is to examine the ef-
fects of differences in national EQ-5D value sets on both absolute and marginal utili-
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ties of health states, and to determine to what degree the differences can be ex-
plained by methodological factors. 
National EQ-5D value sets 
The EQ-5D consists of five domains: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Each domain has three levels, so that a 
total of 243 possible health states can be defined. Each state is described in the 
form of a five-digit code using three levels. Level one means no problems, level two 
indicates moderate problems and level three means severe problems in that do-
main. In general, it is assumed that health utilities are additive and that, conse-
quently, the health utility of someone declines when their health deteriorates [9]. 
With the EQ-5D, the calculation of health utilities is performed using an additive 
formula including coefficients when reporting moderate or severe problems in one 
of the domains, a constant as an extra disutility associated with any deviation from 
full health and the coefficient ‘N3’ whenever reporting severe problems (level 
three) on at least one domain [9,11]. In general, it is assumed that the utility scores 
fall within the 0.0 (dead) to 1.0 (perfect health) value scale. However, people could 
indicate that certain health states are worse than dead and, in that situation, the 
utility score will be below 0.0 [12]. 
The original EQ-5D instrument included utility scores derived from a population 
sample in the UK in the early 1990s [12]. Because using values derived in one coun-
try may misrepresent the values in another country, the EuroQol group has pro-
vided different value sets for different countries [7,13,14]. 
Two valuation methods, time trade-off (TTO) and visual analogue scale (VAS), have 
been used to develop the value sets. For the valuation of the health states, a selec-
tion is made from the 243 possible health states. The selected health states are then 
valued by a sample of the general population. The TTO valuation study is carried out 
in the following way: people are asked to imagine that they will be in a health state 
for 10 years (t) and are then asked to consider a number of shorter periods in full 
health. When the respondents are unable to choose between the 10 years in the 
state and a given duration in full health (x), the value of the state is given as x/t [15]. 
In the VAS valuation study, the respondents are asked to value the health states 
under the assumption that each health state lasts for 1 year. The collected data are 
then rescaled from ‘best imaginable health’ = 100 and ‘worst imaginable health’ = 0 
to a scale where health state 11111 = 1 and dead = 0 [9]. Finally, a regression model 
is applied to derive the coefficients for the value set. However, the selection and 
number of health states and of the study population vary between the valuation 
studies. Furthermore, the two valuation methods can also result in differences be-
tween the value sets. It can be concluded that, in developing the national value sets, 
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various design characteristics were used, which resulted in methodological differ-
ences among the value sets [9]. 
Seven countries performed a TTO valuation study, namely Denmark, Germany, Ja-
pan, the Netherlands, Spain, Zimbabwe and the UK as given in Table 1 [9]. In addi-
tion, eight VAS valuation studies have been carried out, namely in Belgium, Den-
mark, Finland, Slovenia, Spain, the UK and New Zealand. A European value set has 
also been constructed using data from eleven valuation studies in six countries, 
namely Germany, Finland, the Netherlands, Spain, Sweden and the UK. In Table 2, 
all additive VAS value sets are given [9]. 
Methods 
The analyses are based on the value sets that are presented in Szende et al., [9] 
published on behalf of the EuroQol group. All the calculations were carried out with 
the official formulas of the EuroQol group. Three kinds of analyses were performed. 
The first was based on the coefficients in Tables 1 and 2. The second was based on 
two health states and focused on the changes at the margin in utilities caused by 
possible deteriorations in these health states. The third analysis focused on explain-
ing the difference in value sets by methodological differences among the valuation 
studies. 
For the first analysis, the value sets were compared with each other by ranking the 
coefficients of level two and level three for all domains. The coefficients of level two 
and three were subtracted from the utility score for perfect health. A high coeffi-
cient results in a high utility loss when the health-state description of a patient 
scores on that level. By comparing the coefficients in the different value sets, the 
relative importance of the coefficients in all domains was determined. Then, the 
differences between the rankings of all value sets combined were examined by cal-
culating Spearman’s correlation coefficient. The correlation between the rankings of 
the national value sets was calculated with this coefficient. 
In the second analysis, two health states were selected for additional analysis. 
These states (21232 and 33321) are part of the common core states that are often 
included in valuation studies [9]. Furthermore, the selected health states are more 
severe and can clearly indicate the differences between value sets. For example, 
health state 21232 describes a depressed patient, who has moderate problems re-
garding mobility, no problems with self-care, but some problems performing the 
usual activities. Moreover, this patient will experience extreme pain and discomfort 
and some anxiety or depression. In health state 33321, a pain patient will have ex-
treme problems with mobility, self-care and the usual activities. Besides these prob-
lems, the pain patient will have some pain or discomfort, but no anxiety or depres-
sion. The impact of the deterioration of these two health states in one domain on 
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the resulting utilities was calculated. In this analysis, one of the domains from the 
original health state deteriorates one level, going from 21232 to 31232. In this way, 
the marginal value of a decline in the health state can be analysed, which may help 
to identify the magnitude of the differences between two health states as scored 
with a specific value set. Value sets that used similar methodologies in the valuation 
study and countries with both TTO and VAS value sets were compared with each 
other in subgroup analyses. In accordance with Marra et al., [28] 0.05 is the mini-
mally important difference for the EQ-5D. 
Since the differences in value sets lead to differences in the utilities and marginal 
utilities of health states, in the third analysis we examine to what extent these dif-
ferences in value sets can be explained by methodological differences among the 
valuation studies. The units of analysis were the separate value sets as obtained for 
each country using a specific methodology. Since the study design consists of two 
levels, with value sets at the lowest level and countries at the highest level, multi-
level analysis was carried out employing the software MlWin 2.02 [29]. 
The individual coefficients of the value sets were the dependent variables for the 
analyses. A separate multilevel analysis was carried out for each of the twelve coef-
ficients of the value set. The following five methodological factors were included as 
independent variables each time: (i) valuation method used; (ii) N3 variable in-
cluded or not in the analysis to derive the value set; (iii) number of states included 
in valuation process; (iv) the way the questionnaires were administered; and (v) the 
number of people included in the valuation process. The dependent variable N3 or 
N3 penalty value is a continuous variable that indicates the value of the coefficient 
N3, and the independent variable N3 is a dichotomous variable that indicates if the 
coefficient N3 is present or not. A random intercept in the multilevel model re-
flected the differences between countries not explained by the independent vari-
ables included. Since the value sets are treated as population parameters in calcu-
lating the utilities, no random term was included in the multilevel analysis at the 
lowest level. The multilevel analyses were performed for each coefficient of the 
value sets to identify which factor has an influence on the value of that coefficient. 
For reasons of power, factors with a p-value <0.30 were retained in the final analysis 
model. This higher criterion value for the p-value allows for including factors in the 
model in case of a small N, thus compensating for a low power. At the same time, a 
criterion level that is even higher may also lead to including factors that are irrele-
vant and this in turn will decrease the power of detecting really relevant factors. 
The chosen criterion value of 0.30 was considered to be a good compromise in this 
respect [30]. 
The explained variance (expressed in percentages) was calculated to identify to 
which extent the differences between value sets were explained by the methodo-
logical factors. This was done by comparing the between-country variance of the 
random intercept for a model without methodological factors as independent vari-
Transferability of EQ-5D utilities 
 93 
ables to the between-country variance of the random intercept for a model includ-
ing methodological factors that have a p-value ≤0.30. 
Results 
Comparison ranking of scores value sets 
In general, as can be seen in Table 1, the highest rankings in the TTO value sets are 
related to the coefficients mobility and pain/discomfort level three and the lowest 
to usual activities level two. Nevertheless, one notes that the population prefer-
ences between the value sets are diverse, which resulted in a Spearman’s ρ of 
0.764. The Dutch ranking of the coefficients seems to be divergent compared with 
the other value sets. More value is attached to anxiety/depression at level three 
= 0.214) and less value to usual activities at level three. Three coefficients are
 
Table 1 Coefficients of time trade-off value sets. The highest and lowest decrement for a given coefficient 
are presented in bold and brackets indicate the ranking of the coefficients (where 1 is the highest and 10 the 
lowest ranking)  
 
 Denmark 
[9,16]  
Germany 
[9,17]  
Japan [9,18] NL [9,19]  Spain [7,9]  UK [9,12]  Zimbabwe 
[9,20]  
Mean 
Constant −0.114 −0.001 −0.152 −0.071  −0.024 −0.081  −0.100 −0.206 
N3  −0.323  −0.234  −0.291 −0.269  −0.279 
Mobility 2 −0.053 (9) −0.099 (5) −0.075 (7) −0.036 (9) −0.106 (7) −0.069 (9) −0.056 (8) −0.071 
Mobility 3 −0.411 (1) −0.327 (1) −0.418 (1) −0.161 (3) −0.430 (1) −0.314 (2) −0.204 (3) −0.324 
Self-care 2 −0.063 (7) −0.087 (6) −0.054 (9) −0.082 (7) −0.134 (6) −0.104 (6) −0.092 (6) −0.088 
Self-care 3 −0.192 (4) −0.174 (3) −0.102 (5) −0.152 (4) −0.309 (2) −0.214 (4) −0.231 (2) −0.196 
Usual activities 2  −0.048 (10)  −0.044 (10) −0.032 (10) −0.071(9) −0.036 (10) −0.043 (10) −0.039 
Usual activities 3 −0.144 (5)  −0.133 (3) −0.057 (8) −0.195 (4) −0.094 (7) −0.135 (5) −0.108 
Pain/discomfort 2 −0.062 (8) −0.112 (4) −0.080 (6) −0.086 (6) −0.089 (8) −0.123 (5) −0.067 (7) −0.088 
Pain/discomfort 3 −0.396 (2) −0.315 (2) −0.194 (2) −0.329 (1) −0.261 (3) −0.386 (1) −0.302 (1) −0.312 
Anxiety/depression 2 −0.068 (6)  −0.063 (8) −0.124 (5) −0.062 (10) −0.071 (8) −0.046 (9) −0.062 
Anxiety/depression 3 −0.367 (3) −0.065 (7) −0.112 (4) −0.325 (2) −0.144 (5) −0.236 (3) −0.173 (4) −0.203 
a Decrements are all from full health or no problems (level one). 
Constant = extra disutility associated with any deviation from full health; N3 = decrement when at least one 
level three reported on one domain. 
 
The ranking of the coefficients of the VAS value sets is demonstrated in Table 2, and 
again the preferences are not similar, with a ρ of 0.726. The highest and lowest 
rankings in the VAS value sets are similar to the TTO value sets. The ranking of the 
domains self-care and anxiety/depression for the Slovenian value set is equal be-
cause the decrements are the same. The value set for Spain deviates the most from 
(ρ
missing within the German value set, because it was estimated using only statis- 
tically significant variables [17]. 
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the other value sets, with a ρ of 0.564, whereby the most value is attached to self-
care level three (ρ = 0.512) and more value than the average of the other value sets 
to usual activities level three (ρ = −0.06). 
 
Table 2 Coefficients of visual analogue scale value sets. The highest and lowest decrement for a given 
coefficient are presented in bold and brackets indicate the ranking of the coefficients are given (where 1 is 
the highest and 10 the lowest ranking) 
 
 Belgium 
[9,21]  
Denmark 
[9,16]  
Europe 
[9,22]  
Finland 
[9,23,24]  
New Zea-
land [9,25]  
Slovenia 
[9,26]  
Spain [9,27]  UK [9]  Mean 
Constant −0.152 −0.225 −0.1279 −0.158 −0.2041 −0.128 −0.1502 −0.155 −0.163 
N3 −0.256  −0.2288  −0.2165  −0.2219 −0.215 −0.142 
Mobility 2 −0.074 (8) −0.126 (6) −0.0659 
(9) 
−0.058 (9) −0.0753 (7) −0.206 (3) −0.0897 (7) −0.071 (8) −0.096 
Mobility 3 −0.148 (4) −0.252 (1) −0.1829 
(1) 
−0.230 (1) −0.1506 (3) −0.412 (1) −0.1794 (2) −0.182 (1) −0.217 
Self-care 2 −0.083 (7) −0.112 (7) −0.1173 
(5) 
−0.098 (8) −0.0714 (8) −0.093 (8) −0.1012 (6) −0.093 (5) −0.097 
Self-care 3 −0.166 (3) −0.224 (2) −0.1559 
(3) 
−0.143 (5) −0.1428 (4) −0.186 (4) −0.2024 (1) −0.145 (3) −0.171 
Usual activities 2 −0.031 (10) −0.064 
(10) 
−0.0264 
(10) 
−0.047 
(10) 
−0.0136 
(10) 
−0.054 (10) −0.0551 (9) −0.031 
(10) 
−0.040 
Usual activities 3 −0.062 (9) −0.128 (5) −0.0860 
(8) 
−0.131 (6) −0.0272 (9) −0.108 (7) −0.1102 (4) −0.081 (7) −0.092 
Pain/discomfort 2 −0.084 (6) −0.078 (9) −0.0930 
(6) 
−0.111 (7) −0.0798 (6) −0.111 (6) −0.0596 (8) −0.084 (6) −0.087 
Pain/discomfort 3 −0.168 (2) −0.156 (4) −0.1637 
(2) 
−0.153 (4) −0.1596 (2) −0.222 (2) −0.1192 (3) −0.171 (2) −0.164 
Anxiety/depression 2 −0.103 (5) −0.091(8) −0.0891 
(7) 
−0.160 (3) −0.0920 (5) −0.093 (8) −0.0512 (10) −0.063 (9) −0.093 
Anxiety/depression 3 −0.206 (1) −0.182 (3) −0.1290 
(4) 
−0.196 (2) −0.1840 (1) −0.186 (4) −0.1024 (5) −0.124 (4) −0.164 
a Decrements are all from full health or no problems (level one). 
Constant = extra disutility associated with any deviation from full health; N3 = decrement when at least one 
level three reported on one domain. 
 
Some differences between the coefficients can be perceived in the arrangement of 
the TTO and the VAS value sets. In particular, the dissimilarities (ρ = 0.6) between 
the preferences for the coefficient usual activities level three are notable. Further-
more, the absolute values of the coefficients also differ, which could influence the 
utility scores of health states. 
Comparison of health states of two patients 
In the second analysis, the differences between the value sets are examined by 
comparing two health states. First, the utilities of two hypothetical patients are 
shown. It is clear that the utilities differ between the value sets. When the national 
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value sets are identical, the bars representing the utilities will all be the same 
length, indicating that the health states have the same utility. Generally speaking, 
the pain patient has the lowest utility and the depressed patient has the highest, 
but the Dutch value set is the only one in which the pain patient has a higher utility. 
However, the bars in Figures 1a and b, which show the depressed patient and the 
pain patient respectively, are not of equal length. The largest differences in utility 
scores can be seen for the pain patient. According to the Spanish value set, the util-
ity is −0.338, and according to the Zimbabwean value set it is 0.263; a difference of 
0.601. 
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Figure 1a Utilities health state depressed patient (21232) 
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Figure 1b Utilities health state pain patient (33321) 
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Next, the decline of the two health states is used for some comparisons. Figures 2 
and 3 show the marginal differences of the successive health states following the 
starting state. Figure 2 shows 21232 (depressed patient) and Figure 3 shows 33321 
(pain patient). In an ideal situation, if there are no methodological and cultural dif-
ferences, the length of the bars for one specific health state is the same for all value 
sets. The first group of bars in Figure 2 indicates the deterioration of the health 
state of the depressed patient on the domain mobility from level two to level three; 
and the health state is therefore altered from 21232 to state 31232. 
 
In an ideal situation, without cultural and methodological differences, are the bars of for   
example health state 31232 of the same length for all value sets 
 
Figure 2 Decline in marginal utility of health state depressed patient (21232) 
 
The differences between the marginal values on the left side of Figure 2 are large. 
For instance, the marginal values of the Danish and the Zimbabwean value sets dif-
fer substantially. On the right side of Figure 2, the differences are smaller; neverthe-
less the Slovenian and Belgian marginal values are dissimilar. The main distinction 
between the two figures is the magnitude of the increments, in that the differences 
are larger between the TTO value sets than between the VAS value sets. Figure 2 
shows the largest marginal values for state 31 232 with variations from −0.358 in 
the Danish TTO value set and −0.206 in the Slovenian VAS value set to −0.125 in the 
Dutch TTO value set and −0.074 in the Belgian value set. 
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In an ideal situation, without cultural and methodological differences, are the bars of for   
example health state 33331 of the same length for all value sets  
 
Figure 3 Decline in marginal utility of health state pain patient (33321) 
 
The health state of the pain patient has fewer deterioration options because it is 
close to health state 33333. Furthermore, the differences between the TTO and VAS 
value sets are larger for health state 33321 than for health state 21232. The longest 
bars in Figure 3 illustrate health state 33331, where the highest marginal values are 
−0.334 from the Danish TTO value set and −0.111 from the Slovenian VAS value set. 
In general, the TTO value sets have higher marginal values than the VAS value sets. 
However, the differences between the value sets are large, independent of the 
valuation method used. The results indicate that the fifteen national value sets are 
not interchangeable without influencing the utilities. 
Furthermore, subgroup analyses were carried out by looking at the results in Figures 
1, 2 and 3. To start, the value sets that used the same methodology were compared, 
namely the Danish and British TTO value sets and the Danish and Slovenian VAS 
value sets. Several differences larger than 0.05 could be identified between the 
Danish and British TTO value sets. The health states of the depressed patient and 
the pain patient differ by 0.233 and 0.172, respectively. Considerable differences 
could also be seen in the size of the deteriorations. The Danish and Slovenian value 
sets also differ, but the differences are, except for the marginal value for 31232, not 
clinically significant. The countries that have both a TTO and a VAS value set were 
also compared (Denmark, Spain and the UK). Substantial differences could be seen 
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between the countries and between the valuation methods, in that the differences 
between the VAS value sets of Denmark, Spain and the UK were smaller. The largest 
difference in utility was between the two Spanish value sets for the pain patient, 
namely 0.4243. 
Statistical analyses of differences between value sets 
In the third analysis (see Table 3), statistical analyses were carried out to identify to 
what extent the differences between value sets were due to methodological dis-
similarities. The regression weights in the table reflect the degree and direction of 
the influence of a methodological factor on a specific coefficient of a value set. Each 
column in table III illustrates the results of the multilevel analysis for that specific 
coefficient. Because the N is small, not the size, but only the sign of the regression 
weights as well as the p-values are used in interpreting the results in table III. The 
percentages indicate that part of the between-country variance in a specific coeffi-
cient can be explained by methodological dissimilarities. 
 
Table 3 Results of the statistical analyses of five methodological factors (n =15) 
 
 TTO N3 present Number of 
states 
Written ques-
tionnaire 
Sample size Explained per-
centage of the 
between country 
variance 
constant 0.096*** 0.042* 0.012 - - 62.4% 
N3 -0.035** -0.253*** -9.49x10
-4
 - 0.05x10
-4
 96.5% 
MO = 2 - - - -0.038 1.10x10
-3
 8.4% 
MO = 3 -0.102* 0.085 - - - 32.0% 
SC = 2 - - - - - 0% 
SC = 3 - - 1.81x10
-3 
- - 11% 
UA = 2 - 0.016 6.12x10
-4
 - - 25.6% 
UA = 3 - 0.052* - - - 23.4% 
PD = 2 - - - - - 3.6% 
PD = 3 -0.148*** - - - - 67.6% 
AD = 2 - - - -0.035* - 18.3% 
AD = 3 -0.155** - -6.18x10
-3
* - - 31.6% 
* : p-value ≤ 0.05; **  : p-value ≤ 0.01; ***: p-value ≤ 0.001 
 
The methodological factors with the smallest p-values are the valuation method 
used and N3 present or not. The TTO value sets have a significantly higher constant 
than the VAS value sets, but a significantly lower N3 coefficient. Furthermore, the 
valuation method has a significant influence on the coefficients for mobility level 
three, pain/discomfort level three and anxiety/depression level three. The presence 
of N3 or not has a significant positive influence on the coefficient for usual activities 
level three. Other factors that have a significant influence are the number of health 
states on the coefficient for anxiety/depression level three and the way of adminis-
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tering the questionnaire on anxiety/depression level two. It is possible that anxi-
ety/depression level three was not often included in the valuation subset, which 
may have influenced the estimation of its coefficient. High explained variances 
mean that a large part of the differences between the national value sets can be 
explained by methodological factors. The percentages range from 96.5% for coeffi-
cient N3 to 0% for self-care level three. In most cases, the explained variance is high 
when one or more methodological factors have a significant influence on the coeffi-
cient. The coefficient N3 penalty value has a high explained variance, which is 
mainly caused by the high significance of the factor N3 present. However, the be-
tween-country variance was not only explained by this factor, but also by the factor 
TTO. Still, 3.5% of the between-country variance remains unexplained, which shows 
that the dependent and independent variables of N3 are not the same. In addition, 
the explained variance for the coefficient usual activities level two is 25.6%, even 
though none of the factors have a significant influence. The two factors alone have 
only a marginally significant influence, but, when the two are combined, the ex-
plained variance is reasonable. 
Discussion 
Differences between EQ-5D value sets 
The main finding of our study is that the differences between national EQ-5D value 
sets are substantial and should not be ignored. Therefore, it is not advisable to use 
utilities from other countries blindly. Transferring the results of cost-utility analyses 
without adjusting the utility to the decision country could result in inaccurate con-
clusions. However, the large methodological differences probably overwhelm the 
difficulties related to the cultural differences between the countries of the value 
sets, which make it harder to speculate on the effects of the differences. The magni-
tudes of the coefficients vary to a great extent, which causes dissimilarities between 
value sets, resulting in different utilities when calculating the utility score of a health 
state. The ranking of the coefficients also shows differences, indicating that not all 
national populations prefer the domains in the same order. These differences could 
be seen between the TTO and VAS value sets, but also within the TTO and VAS value 
sets of the different countries. Furthermore, when looking at two particular health 
states, the largest difference in the utility between two value sets for the pain pa-
tient (33321) was more than 0.6. As the minimally important difference for the EQ-
5D is 0.05, a difference of 0.6 between value sets is substantial [28]. 
The differences between the value sets can be partly explained by methodological 
differences. The multilevel analysis indicates that the valuation method (TTO vs 
VAS) and the presence of the N3 coefficient are important methodological factors, 
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accounting for a large part of the differences. In addition, the importance of the 
method of administering the questionnaire could be explained by the idea that 
when using a written questionnaire, instead of a face-to-face interview, people are 
less inclined to a give a socially desirable answer, possibly resulting in a lower value 
for that coefficient. This could explain the significance of the method of administer-
ing the questionnaire for anxiety/depression level two. A study by Levy et al. [10] 
supports the idea that methodological differences have a large influence on the dif-
ferences between value sets. The remaining differences may reflect cultural dissimi-
larities between countries. However, other methodological differences that were 
not included in the multilevel analysis could also have some influence. 
Limitations of the study 
Two limitations can be mentioned with regard to this study. The first limitation is 
that within this study only two health states were utilized to determine the influ-
ence of deteriorations on the utilities of health states. Furthermore, the chosen 
health states (21232 and 33321) were more severe states for which the differences 
between the value sets are larger. The differences are smaller in less severe health 
states, as can be seen in Szende et al. [9] However, these health states clearly illus-
trate the potential consequences of different national value sets on utilities and 
marginal utility values. 
The second limitation is that the number of value sets is relatively small and there-
fore the statistical power is limited. This implies that the set of methodological fac-
tors that are significant will be a ‘conservative’ set. If the sample size of the study 
had been larger, possibly additional methodological factors that influenced the 
value sets would have been identified. This was partly accounted for in the present 
study by increasing the criterion value for the p-value to 0.30. Furthermore, the re-
sults of the statistical analysis cannot be interpreted as a causal connection be-
tween the factors and the coefficients, because it is not clear whether all relevant 
methodological factors were included. One potential factor is the selection for core 
health states in the valuation study. This factor could not be taken into account, 
because it was not always clear which health states were used. Consequently, the 
results should be interpreted with caution. 
Implication of the results 
We suspect that in practice value sets are utilized without regard to country, in that 
the British value set of Dolan [12] is commonly used together with another value set 
to see if conclusions vary. The results of this research indicate that the differences 
between the value sets are considerable, partly as a consequence of methodological 
differences. The dissimilarity between the two valuation methods, TTO and VAS, is 
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not the only relevant methodological difference. Accordingly, the normal practice of 
mixing the different value sets is not advisable. The differences can influence the 
results of the economic evaluation. 
In the Dutch MEDICIE (Maastricht Evaluation of a Diagnostic Intervention for Cogni-
tively Impaired Elderly) study, [31] the cost effectiveness of an integrated multidis-
ciplinary diagnostic facility for ambulant psychogeriatric patients was compared 
with usual care. This dataset was used to examine the influence of the differences 
between the fifteen value sets on real data. All value sets were applied to this data-
set to calculate the utilities. The incremental cost-effectiveness ratio (ICER) was 
then calculated. The largest differences between the TTO value sets could be identi-
fied between Japan (ICER of €9988 per QALY) and Spain (ICER of €4287 per QALY). 
The largest differences between the VAS value sets could be seen between Finland 
(ICER of €6853 per QALY) and Belgium (ICER of €5548 per QALY). These differences 
are considerable and may influence the final results of economic evaluations, de-
pending on the ICER estimate in relation to the cost-effectiveness threshold. 
Our results show that the methodological differences have a large influence on the 
value sets, but the extent of the cultural differences remains unclear. Therefore, at 
this moment our advice is to utilize, whenever possible, the value set of the country 
in which the economic evaluation is carried out. In addition, we recommend using 
the value set of the decision country when the results of an economic evaluation 
are transferred. Therefore, whenever possible, the raw data of the original trial 
should be used to calculate the utilities for the decision country. However, it is not 
clear at the moment which valuation method results in the most valid value set. As 
a result, it is difficult to advise which strategy should be used in the case of a multi-
national trial. 
Conclusion 
More research is needed on the transferability of utilities across countries. This arti-
cle is one of the first to focus on the transferability of utilities, and the conclusion is 
that EQ-5D value sets are not easily transferable. However, the differences between 
the value sets are partly caused by methodological differences. Therefore, further 
research should focus on investigating the most valid method for determining new 
value sets to calculate utilities for health states or to agree on a standard to perform 
these studies for the reason of possible comparison. To the extent that the cultural 
differences underlying the differences in the national value sets are not significant, 
establishing a gold standard for estimating value sets may then offer opportunities 
for transferring utilities of the EQ-5D. 
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Chapter 7 
General discussion  
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In this thesis several aspects related to the problems of transferring economic 
evaluations are investigated. The focus of the research is on the international as-
pects of transferring economic evaluations. As indicated in the introduction, prob-
lems related to the transferability of economic evaluations can be identified in the 
design, analyzing or reporting stage when performing studies, and in the diagnosing 
or adapting stage when interpreting studies (see Figure 1, Introduction). The prob-
lems related to transferring data discussed in this thesis belong to the diagnosing 
stage when interpreting economic evaluations from other jurisdictions. The results 
indicate that transferring economic data is not as straightforward as it is sometimes 
considered, but that methods that help to assess the transferability of cost-
effectiveness results make a difference. Furthermore, it became clear that not only 
factors related to the transferability of health care costs should be considered, but 
also that other transferability factors - such as lost productivity and utilities - could 
hinder the transferability of the data. The overall objective of the thesis is to explore 
in the diagnosis stage of economic evaluations, methods for transferring cost-
effectiveness estimates and costs and effect values between jurisdictions. 
Main findings 
Box 1: Main findings 
• Transferability issues can not be neglected in a decision making context 
• Using Welte’s model leads to different cost and effect estimations 
• Large differences between recommendations in national pharma-
coeconomic guidelines regarding lost productivity  
• Between country difference when measuring lost productivity  
 EQ-5D value sets differ between countries, partly due to methodologi-
cal differences  
 
The issue of transferring economic evaluations across jurisdictions is receiving more 
and more attention in the literature. There is a short description of the current lit-
erature on transferability in Chapter 2 [1]. It becomes clear that decision makers are 
willing to use data collected in other jurisdictions due to the growing demand for 
economic evidence and the limited resources for carrying out economic evaluations. 
It is also explained which steps should be taken to assess the transferability of data 
across jurisdictions. It is very important that decision makers are aware that several 
factors could affect the transferability of data. 
In the last decade, several methods have been developed for evaluating the trans-
ferability of economic evaluations. Welte’s model is the first method for assessing 
the transferability of economic evaluations [2]. Chapter 3 presents a case study 
•
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which tested Welte’s model, by comparing two predictions from foreign studies 
with the results of a Dutch study. The first “all studies prediction” consisted of all 
foreign studies and the other, so-called “Welte’s model prediction”, used only stud-
ies that passed the criteria of Welte’s model. The two predictions lead to different 
results, which indicates that using Welte’s model does influence both cost and ef-
fect estimates [3]. 
At the moment there is no international consensus on whether and how the value 
of lost productivity should be included in economic evaluations. Recommendations 
are given in national pharmacoeconomic guidelines on how economic evaluations 
should be designed, executed and reported in a particular jurisdiction, but these 
recommendations vary. In Chapter 4 it is shown that this lack of consensus has re-
sulted in diverse recommendations for different jurisdictions. Most national phar-
macoeconomic guidelines recommend including the costs of absenteeism from paid 
and/or unpaid work. However, no agreement exists on the valuation of lost produc-
tivity. These different recommendations hinder the transferability of data regarding 
the value of lost productivity across jurisdictions, as quantity estimates are likely to 
differ [4]. 
Different measurement methods will lead to different estimates of lost productivity; 
consequently, lost productivity should be measured using the same instrument in 
various countries. Chapter 5 presents evidence that the country in which the data 
are collected has a significant influence on whether a respondent has been absent 
during the last three months and on the quality of work on the last working day. 
However, no significant differences between the four countries were found in the 
number of days of absence and the overall scale of presenteeism. Other variables 
related to patient characteristics, disease severity, quality of life, job characteristics 
and disability insurance also have a statistical significant influence on lost productiv-
ity. Nevertheless, it is advisable to be careful when using data about lost productiv-
ity from other jurisdictions since the estimation from the study country could over- 
or underestimate the lost productivity in the decision country [5].    
Most research on transferability issues focuses on the problems related to transfer-
ring health care costs across jurisdictions. In contrast, it is not clear if utilities, espe-
cially those of the EQ-5D, can be transferred without problems. In Chapter 6 the 
differences between the national value sets of the EQ-5D were analysed in several 
ways [6]. The results show that there are considerable differences between the 
value sets, resulting in different utilities for the same health state in different coun-
tries. Methodological differences between the valuation studies can explain some of 
the differences, and those that remain probably reflect cultural differences between 
countries. 
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Considerations 
Box 2: Main considerations 
• Balance between need of transferability adjustment versus degree of 
generalisability  
• At the moment no adaptation tool available 
 Dissimilarities between economic evaluations from different jurisdicti-
ons caused by methodological and cultural differences 
 
There are differences between transferability factors as to which degree adjust-
ments are needed. Figure 1 presents the balance between the need for transferabil-
ity adjustment and the degree of generalisability of several factors is given. In Figure 
1 the factors investigated in this thesis and the factors that, according to Welte et 
al. [2] are specific knock-out criteria, are listed in relation to the need for transfer-
ability adjustment and the degree of generalisability. For example, for the factor 
‘absolute and relative prices’, a high degree of transferability adjustment is needed, 
meaning that the factor should be adapted when it is transferred across jurisdic-
tions. It has to be kept in mind that the transferability adjustment a factor needs is 
the opposite of the degree of generalisability of that factor, so when a factor is 
highly generalisable then the need for transferability adjustment is low. This need 
for adjustment is important in the adaptation stage of economic evaluations as it 
indicates to what degree factors have to be adjusted for other jurisdictions. How-
ever, the degree of adjustment needed does not provide any information on how 
difficult it is to adapt a specific factor.  
The results in this thesis clearly indicate that Welte’s model has an added value for 
assessing the transferability of data that EQ-5D-derived utilities and lost productiv-
ity data are not generalisable and that adaptation is needed. However, it is not clear 
how complete economic evaluation studies, utilities or absenteeism and presentee-
ism data should be adapted to make it possible to transfer these data to other juris-
dictions, which as explained in the introduction is the second stage when interpret-
ing economic evaluations. In addition, there is no tool available for adapting data so 
that the information can be used in jurisdictions other than the study country. At 
the moment, such an adaptation tool has not yet been developed. The research 
described focused on the diagnostic stage and not on the adaptation stage. As a 
result, as Figure 1 shows, more knowledge is available about the need to adjust the 
transferability of two specific factors. However, no knowledge was derived on how 
the factors might be adapted in order to transfer the data to other jurisdictions.  
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Need for transferabil-
ity adjustments 
 
Degree of  
generalisability 
  
Absolute and relative prices 
Discount rate 
Perspective 
 
Productivity cost approach 
 
Value of lost productivity /  
productivity and work-loss time* 
 
 
Utilities / health status preference* 
 
 
 
Medical cost approach 
 
 
 
 
Relative clinical effectiveness 
 
 
 
The need for transferability adjustment is not clear for the factors: 
Practice variation 
Technology availability 
Case-mix 
Acceptance, compliance and 
incentives to patients 
Disease spread 
Life expectancy 
Incidence and prevalence 
 
The need for transferability adjustment from the factors with * is identified in this thesis 
 
Figure 1 Balance between the need for transferability adjustment and the degree of gener-
alisability 
 
Several types of methodological difference can be found between economic evalua-
tions regarding for example discount rate, perspective and lost productivity. These 
differences can be the result of dissimilar recommendations in the national pharma-
coeconomic guidelines and of the different methods used to measure and value 
both costs and effects. An example of differences caused by differences in meth-
odological guidance can be seen in Chapter 4. In this chapter it was indicated that 
there are considerable differences among the national guidelines concerning rec-
ommendations for the valuation of lost productivity [4]. As a consequence, lost pro-
High 
 
Low 
 
Low 
 
High 
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ductivity is valued using two different methods, namely the Friction Cost Approach 
or the Human Capital Method. These different valuation methods result in different 
cost estimates for lost productivity [7]. The consequence of these differences in 
methodological guidance is that the possibility for transferring study results is hin-
dered. Another problem caused by methodological differences is that it is hard to 
detect if any differences found are cultural differences or differences in methodo-
logical guidance. For example, it is not clear if transferring utilities really needs low 
adjustments, as can be seen in Figure 1, or if utilities differ highly between jurisdic-
tions due to large cultural differences. Furthermore, it can also be questioned 
whether EQ-5D value sets themselves are reliable and repeatable, or if they can 
cause a type of methodological bias. It is not clear whether national value sets will 
be the same when the valuation process is repeated: thus if, for example, the re-
search were to be repeated in the Netherlands, the derived value set will be compa-
rable with the current Dutch value set. Cultural differences between jurisdictions 
can be seen as differences in, for example, population preferences for specific heal-
th care technologies, the valuation of health, differences in clinical practice and 
ethical and legal regulations. Possible cultural differences are not taken into account 
in most economic evaluations, even though results could be affected. This thesis 
does not take possible cultural differences into account either, mainly because of 
the complexity of measuring and including culture in economic evaluations. Never-
theless, cultural differences could explain some of the differences found among the 
results of economic evaluations carried out in multiple countries. Another problem 
is that it is not clear how results should be adapted to make it possible to transfer 
the data if any cultural differences are found between jurisdictions.  
Recommendations 
Recommendations for transferability related problems  
Box 3: Transferability issues 
• Reduce variation between recommendations by developing an interna-
tional guideline 
• Reduce variation between recommendations by developing an interna-
tional reference case  
• Transparent reporting of costs and effects 
 Standardisation beneficial for small countries and low and middle inco-
me countries  
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As indicated before, there are several differences between national pharma-
coeconomic guidelines [8, 9]. This hinders the possibility of transferring data across 
jurisdictions, especially between jurisdictions in which the guidelines differ to a 
great extent. The different recommendations result in different ways of collecting or 
valuing data, restricting the possibility for using or transferring data that is collected 
or valued in other jurisdictions.   
There are several options for reducing the variation in the recommendations be-
tween the national pharmacoeconomic guidelines. One option is to focus on the 
development of an international or European guideline for economic evaluations. In 
this guideline the focus should be on the standardization of data collection and 
methodological guidance. Some attempts have already been made to develop gui-
delines that are not country specific. One of the most recent examples is the HTA 
Core model of EUnetHTA [10]. The problem, however, is that this model is quite 
extensive, the recommendations are not always very clear and therefore the model 
has a limited practicability for daily use. In addition, other attempts to develop an 
international guideline have not been able to reach consensus on, for example, the 
preferred perspective and what costs should be included in economic evaluations. It 
is believed that many attempts have failed, due to the lack of accommodation for 
individual or national requirements. These requirements are necessary as decision 
making processes differ between jurisdictions due to different legal conditions and 
cultural understanding in each country [11]. Furthermore, international consensus 
on several elements of an economic evaluation should be reached. In spite of these 
problems, it could be useful to try to develop an international pharmacoeconomic 
guideline.  
The development of an international guideline will take some time and effort. The-
refore, another option is to develop an international or European reference case 
instead of an international pharmacoeconomic guideline, as for example the refer-
ence case as developed by the US Panel [12]. Furthermore, the use of an interna-
tional reference case will ease the transferability of economic evaluations, as it will 
be easier to compare results across countries. In such a reference case all elements 
have to be calculated and reported in the same way. However, by using a reference 
case instead of an international guideline the possibility of including national ele-
ments that use different methods remains. This is important as national prefer-
ences, health care systems and decision making processes differ across jurisdictions. 
For example, it could be decided that the discount rate for both costs and effects 
should be 4%, but the results of using a discount rate of 3% can also be reported. 
The use of a reference case can be enforced by the major international journals 
making it compulsory to report the results of economic evaluations in line with the 
reference case. In addition, the results can be reported according to the national 
guidelines.  
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One of the problems that arise when trying to interpret foreign economic evalua-
tions is that the design and results of the study are often not reported transpar-
ently. Therefore, often it is not clear how both costs and effects were measured and 
calculated in economic evaluations. This lack of transparent reporting hinders the 
assessment of whether resource use and the price of a health care technology are 
comparable across jurisdictions. When all units, for example resource use and costs, 
of both costs and effects, are reported separately and transparently it simplifies the 
assessment of the data.  
A more standardised way of performing economic evaluations would also benefit 
small countries and low and middle income countries, as it is very difficult for these 
countries to carry out economic evaluations themselves. These countries do not 
have enough resources to carry out the studies needed for the decision making 
process on the reimbursement of new health care technologies. Therefore, these 
countries must use economic evaluations that have been carried out in other juris-
dictions. However, the different national pharmacoeconomic guidelines make it 
more difficult to assess the transferability of data. The consequence is that for every 
study, the differences between the study country and the decision country have to 
be assessed; this costs both money and time, which makes it harder to transfer 
data. Therefore, standardisation of methods and reporting could simplify the as-
sessment of data for these countries.  
 
Recommendations for further research 
Box 4: Further research  
• Focus on the development of an adaptation tool  
• More research is needed on other transferability factors  
 Focus on development of overall method for assessing transferability  
 
Although the research presented here is a step forward in transferability research, 
several topics related to transferability have not been addressed. As described in 
the introduction, transferability issues can arise when performing and interpreting 
economic evaluations. Two stages can be distinguished when interpreting economic 
evaluations. The research in this thesis focused on the diagnosing stage when inter-
preting economic evaluations and not on the other stages in which transferability 
issues arise. Until now, a limited number of studies have been carried out that fo-
cused solely on the adaptation stage, which is the last stage when interpreting eco-
nomic evaluations from other jurisdictions. An example of a study in which both the 
diagnosis and adaptation stages of economic evaluations are incorporated is the 
study of Essers et al. (2010). In this study the transferability of a model-based eco-
nomic evaluation from the United Kingdom was first assessed – the diagnosis stage - 
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and then the different parameters were adapted [13]. However, this is one of the 
few studies in which an economic evaluation was adapted. Therefore, it is impor-
tant to develop straightforward tools to adapt economic evaluations data in order 
to transfer data to other jurisdictions. An example of such an adaptation tool could 
be an algorithm for transferring utilities across countries. The main advantage of 
such an adaptation tool is that it would not be necessary to collect data all over 
again. However, adaptation tools should be developed for a range of factors, which 
will take some time. On the other hand, adaptation tools do not have to be devel-
oped for each transferability factor, because some factors are relatively easy to 
adapt. With some other factors, adaptation is not possible or the transferability of 
the factor depends on the technology, as, for example, with clinical practice.   
Due to the strong focus on the transferability of direct health care costs, limited 
knowledge is available on the influence of other factors that could hinder the trans-
ferability of economic evaluations. Examples of such factors are the possible differ-
ences in the valuation of health or health state preferences between jurisdictions, in 
resource use, in the epidemiology of the disease and demographic differences be-
tween patients. These factors could have a large impact on the effectiveness and 
costs of a health care technology, but are not often taken into account when trans-
ferring results.  
At the moment, there are a number of methods available for assessing the transfer-
ability of economic evaluations. These methods can be helpful when diagnosing 
economic evaluations from other jurisdictions. Not all methods have already been 
tested or validated, making it unclear whether using one or another of these specific 
methods really helps in assessing the transferability of data. Furthermore, it is not 
practical to have several methods available as it not clear whether the methods as-
sess the same issues. Therefore, it is advisable to develop a new method. In this 
new method the strong points of the already existing methods should be combined 
with each other as much as possible. For example, the different steps of the method 
of Welte et al. [2] and the quality check included in the method of EURONHEED [14, 
15] could be included. Furthermore, the latest insights on transferability issues have 
to be included in the new method. It is preferable that it be clear whether the new 
method can be used for trials and/or modelling studies. Due to the different nature 
of trial-based economic evaluations and modelling studies it is likely that a different 
assessment method has to be developed for each type of economic evaluations.  
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Implications for decision makers  
Box 5: Implications for decision makers 
• Problems with using foreign economic evaluations 
• Look critical at foreign data because of differences between guidelines 
 Use assessment tool when looking at foreign data  
 
As a result of the increasing demand for economic evaluations of health care tech-
nologies for decision making, pressure arises to transfer data across jurisdictions [2]. 
The problem is that economic evaluations or its results do not travel well, due to 
differences between jurisdictions, especially between health care systems [16]. De-
cision makers have to become aware that these differences can be so considerable 
that the transferability of data is hindered, as has been shown in this thesis. How-
ever, economic evaluations from other jurisdictions could be the only economic 
data available at a certain moment, and due to time constraints or limited resources 
it is not likely that an economic evaluation for that technology will be carried out in 
due time. This lack of data from the own jurisdiction can lead to the question of 
whether the results and conclusions of economic evaluations carried out in another 
jurisdiction can be used. Moreover, decision makers have to become aware that is 
important to determine whether the values of the most important parameters are 
relevant in their own jurisdiction [17]. When the values of the most important pa-
rameters are used without adaptation, it can lead to under- or overestimation of 
the ICER. Moreover, using the under- or overestimation of the ICER could lead to 
making the wrong decision [2]. 
Decision makers need to be more aware that the utilisation of foreign data is not 
just a matter of copying the results, as this can lead to invalid conclusions. It is im-
portant to be aware that a critical eye must be cast on all economic evaluations that 
are available for each specific decision. This critical attitude is needed not only to-
wards the direct health care costs, but also on particular aspects of economic 
evaluations as these can differ greatly between settings [18, 19]. In addition, it is 
important to identify if all relevant aspects, both costs and effects, are taken into 
account in the economic evaluation. Methods can differ between jurisdictions, re-
sulting in different ways of collecting and valuing this data. It is therefore possible 
that not all data that are relevant in a specific jurisdiction are also relevant in other 
jurisdictions; consequently some relevant data might not be collected. 
Therefore, it is advisable for decision makers to assess if the foreign data are rele-
vant within their own decision making context. Within such an assessment a judge-
ment will be made whether the study setting is comparable with the decision set-
ting. At the moment, several methods are available that could help decision makers 
to assess the transferability of economic evaluations. These methods help to assess 
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the transferability of data in a systematic way, by looking critical at the intervention 
and comparator used in the study and at different factors that could hinder the 
transferability. Using existing models decreases the possibility that important ele-
ments that are not transferable might be overlooked. Furthermore, the results of 
the assessment can be helpful in various ways, clarifying whether the data can be 
used directly without any adaptation, whether the data should be adapted to the 
new setting, or whether new data have to be collected. Sometimes the best option 
will be to combine the use of foreign data with a limited data collection in the own 
setting. Although it will be more time consuming than using only foreign data, it will 
be less time consuming than performing a completely new study. Furthermore, the 
use of some elements of foreign studies will be informative on what kind of data 
should be collected in the own jurisdiction. Regardless of the decision being made it 
is important to be transparent about transferability issues within all steps.  
Main conclusions 
The research described in this thesis adds knowledge on issues regarding the trans-
ferability of economic evaluations. It has become clear that assessing the transfer-
ability of economic evaluations by using a diagnostic tool results in different estima-
tions in comparison with using the foreign results directly. Using such a diagnostic 
tool also helps in providing awareness where possible transferability problems could 
arise. However, it does not help to adapt the data to the decision country. More 
knowledge was also generated on two specific transferability factors. Recommenda-
tions in national pharmacoeconomic guidelines differ, in particular on the identifica-
tion and valuation of the value of lost productivity. This is the result of the debate 
on whether and how lost productivity should be included in economic evaluations. 
Furthermore, a comparative study in four European countries on both absenteeism 
and presenteeism discovered that these quantities sometimes differ significantly 
across countries. In addition, it has become clear that EQ-5D-derived utilities differ 
when using other national value sets; this is caused in part by the different methods 
that are used to develop the value sets. All these results illustrate that not only di-
rect health care costs, being both the prices and quantities, differ between jurisdic-
tions, but also that other elements of economic evaluations differ. Therefore, other 
transferability factors must also be assessed when using economic evaluations from 
other jurisdictions. Further research should focus on three different problems re-
lated to transferability. First, attention should be directed on developing an adapta-
tion tool which enables the transfer of data to other jurisdictions. Second, research 
must be carried out on other factors that could influence the transferability of eco-
nomic evaluations, in particular factors that are not related to direct health care 
costs. Third, a new method for diagnosing or assessing the transferability of eco-
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nomic evaluations should be developed, combining the strong points of existing 
methods and adding the newest insights on transferability.  
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Summary 
As indicated in Chapter 1 is the utilisation of economic evaluations to guide the de-
cision making process about the reimbursement of new health care technologies 
growing. Health technologies can thereby be understood as technical equipment, 
but also as procedures or structures in prevention, diagnostics, therapy or rehabili-
tation. In addition, a growing number of national pharmacoeconomic guidelines are 
developed to indicate how economic evaluations should be carried out. Due to the 
growing request for economic evaluations and due to scarce resources (for instance 
time and research funding) it is not always possible to perform all studies in the own 
jurisdiction. Therefore, most health care technologies are analysed in a limited 
number of jurisdictions. As a consequence, results of economic evaluations carried 
out in other jurisdictions have to be transferred to jurisdictions of decision makers 
who would like to use the results to guide their decision making processes. When 
interpreting economic evaluations carried out in other settings two stages can be 
distinguished. In the first stage the focus in on diagnosing the transferability of the 
data and the second stages is focused on the adaptation of the data. The research 
described here focused on diagnosing the transferability of economic evaluations 
that are already carried out. The transferability of different elements of economic 
evaluations is assessed in the diagnosing stage. For decision makers is the diagnos-
ing stage very important as they must consider whether the costs and effects esti-
mated collected in other jurisdictions can be used for their own setting. Although it 
is sometimes seems necessary to use economic evaluations from other jurisdictions 
due to lack of data from the own jurisdiction, a critical look is necessary at the us-
ability of these data.    
 
In Chapter 2 it becomes clear that there is growing pressure on decision makers to 
use scarce resource for health care as efficient as possible. It is not possible to carry 
out every study in the own jurisdiction and it will lead to inefficient use of resources. 
The consequence is that decision makers should have to asses whether economic 
evaluations performed in other jurisdictions are suitable for the new decision mak-
ing context. Unfortunately, results of economic evaluations cannot be used without 
adaptation, because health care systems, legal frameworks and other transferability 
factors differ between jurisdictions. The result is that economic evaluations are not 
easily transferable and that decision makers should be aware of this.  
 
Chapter 3 describes the testing of Welte’s model with a case study as an example. 
Welte’s model is a method to assess the transferability of economic evaluations. 
During the assessment of the economic evaluation general and specific knock-out 
criteria are used. In the study foreign economic evaluations were transferred to the 
Netherlands by combining the results in two predictions and the predictions were 
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compared with a Dutch reference study. In the “all studies prediction” data from all 
foreign studies were included, but in the “Welte’s model prediction” only data from 
studies that were considered to be transferable were included. From the total of 
fourteen studies, all fourteen were included in the “all studies prediction”, but only 
seven were considered to be transferable and used for the “Welte’s model predic-
tion”. The results from both predictions differ, nevertheless the costs were better 
predicted in the “Welte’s model prediction”.  However, the effects were better pre-
dicted in the “all studies prediction”. Therefore, it can be concluded that the utilisa-
tion of Welte’s model influence cost and effect estimates when assessing the trans-
ferability of economic evaluations from other jurisdictions. 
 
In Chapter 4 the consequences of the debate on whether and how to include the 
value of lost productivity on the recommendations in national pharmacoeconomic 
guidelines can be seen. Guidelines have been developed to guide the design and 
execution of economic evaluations in specific jurisdictions. The recommendations in 
the thirty national guidelines reviewed, differ to a great extent. First of all, not all 
guidelines recommend performing economic evaluations from the societal perspec-
tive. In addition, the analyses showed that the recommendations regarding what 
kind of lost productivity differ slightly, but most guidelines recommend including 
the costs of absenteeism. Furthermore, no agreement can be found on how lost 
productivity should be valued. These different recommendations on the preferred 
perspective and lost productivity hinder the transferability of the data. The differ-
ences between the recommendations on the identification and measurement of 
lost productivity are probably caused by the debate and lack of consensus on the 
inclusion of the value of lost productivity in economic evaluations.   
 
While Chapter 4 concentrated on the methodological differences when including 
lost productivity in economic evaluations, Chapter 5 concentrates on the differ-
ences in lost productivity between countries when using the same method in the 
same population. To investigate whether country of residence has a significant in-
fluence on the quantity of lost productivity differs between countries, respondents 
with a rheumatic disorder from four European countries filled out an online ques-
tionnaire. This questionnaire included items about lost productivity, but also con-
tained questions about patient and job characteristics, disease characteristics, qual-
ity of life and disability insurance. The data were analysed using logistic and linear 
regression analyses, in which different components of lost productivity were the 
main outcome measures and correction took place for the other variables. From the 
results it becomes clear that country has in some cases a statistical significant influ-
ence on lost productivity, namely on having been absent in the last three months 
and quality of work on the last working day, and that the other variables such as 
quality of life and job characteristics also influence lost productivity. Looking at the 
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results it can be concluded that is not advisable to transfer lost productivity data 
because of the differences in these data between countries, but that these should 
be measured in the own decision country.  
 
The transferability of EQ-5D derived utilities is discussed in Chapter 6. It was unclear 
whether utility scores are transferable between jurisdictions, notwithstanding the 
standard practice of using utilities directly without adaptation. The EQ-5D can be 
used to describe health states and consists of five domains with three levels. At the 
moment several national value sets are available and therefore it can be used for 
comparing utility scores across countries. The comparison of the value sets was car-
ried out by looking at the relative importance of the EQ-5D domains and the abso-
lute and marginal utilities of two health states. Furthermore, the role of methodo-
logical differences in the valuation studies to develop the value sets was examined. 
Differences were perceived in the preferences for the domains, but in general the 
domains mobility and anxiety/depression were the most preferred. The utility 
scores for the two health states differed substantially, which the largest differences 
of 0.601 on a scale of -1.0 and 1.0 could be found between Spain and Zimbabwe. 
Furthermore, the differences between the marginal values are substantial. These 
differences between the value sets could be partly explained by the methodological 
differences. All results indicated that the differences between the value sets are 
considerable and that these should not be ignored.  
 
In the general discussion in Chapter 7 was the overall thesis discussed and recom-
mendations were given for transferability related problems and for further re-
search. It can be concluded that the research described in this thesis have resulted 
in more knowledge on several aspects of the transferability of economic evalua-
tions. This gained knowledge was used to develop a figure in which the balance for 
some transferability factors between the need for transferability adjustment and 
the degree of generalisability is expressed. The factor absolute and relative prices, 
for example, needs to be adjustment and has a low degree of generalisability, but 
the opposite seems true for relative clinical effectiveness. The results showed that 
using Welte’s model to assess or diagnose the transferability of economic evalua-
tions will lead to different results than using foreign data without assessment. In 
addition, the need for transferability adjustment for two transferability factors, be-
ing utilities and lost productivity, has become clear. The results also indicate that 
transferability related problems are partly caused by variations between countries 
in methodological guidance for economic evaluations. These differences can be di-
minished by developing an international pharmacoeconomic guideline or an inter-
national reference case, but the development of an international reference case will 
be more realistic than an international guideline. In this international reference case 
all elements of an economic evaluation have to be calculated and reported in the 
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same way, but the possibility remains to include national elements in an economic 
evaluation. The use of a more standardised way of performing economic evalua-
tions will also be beneficial for small countries and low and middle income countries 
as it will be easier to assess the transferability of the studies. Several recommenda-
tions for further research are given. It would be advisable to develop a new method 
to assess the transferability of economic evaluations in which the latest insights in 
transferability are included. Other research should focus on the need for transfer-
ability adjustment for other transferability factors and on the development of an 
adaptation tool. Finally, through the results presented in this thesis the importance 
of transparent reporting of economic evaluations and the importance of transpar-
ency when diagnosing the transferability of economic evaluations is indicated. Since 
in this way more clarity can arise on the transferability of economic evaluations.   
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Samenvatting 
Zoals aangegeven in hoofdstuk 1 worden economische evaluaties steeds meer ge-
bruikt om besluiten over vergoedingen van nieuwe zorgtechnologieën te onder-
bouwen. Onder zorgtechnologieën worden zowel technische apparatuur, maar ook 
procedures of processen bij preventie, diagnostiek, therapie of revalidatie verstaan. 
De wijze waarop economische evaluaties moeten worden uitgevoerd, wordt steeds 
vaker en in steeds meer landen vastgelegd in farmacoeconomische richtlijnen. Deze 
richtlijnen worden specifiek voor een land (nationaal) of voor een gedeelte van een 
land (jurisdictie) ontwikkeld. Hierdoor ontstaan er problemen bij het toepassen van 
de resultaten van economische evaluaties in een andere jurisdictie dan de jurisdictie 
waarin de economische evaluatie is uitgevoerd. Deze vertaalslag staat bekend onder 
de noemer transfereerbaarheid of transferabiliteit. Door de groeiende vraag naar 
economische evaluaties en vanwege schaarse middelen - bijvoorbeeld door gebrek 
aan tijd en onderzoeksfinanciering – is het niet altijd mogelijk om alle economische 
evaluaties in de eigen jurisdictie uit te voeren. Daardoor worden de meeste zorg-
technologieën slechts in een beperkt aantal jurisdicties geëvalueerd. Als gevolg 
daarvan moeten de resultaten van economische evaluaties uit andere jurisdicties 
worden getransfereerd naar de jurisdictie van de beleidsmakers die de resultaten 
van economische evaluaties willen gebruiken voor hun eigen besluitvormingspro-
ces. Wanneer economische evaluaties uit andere settings worden gebruikt, kunnen 
twee verschillende fases worden onderscheiden. In de eerste fase ligt de focus op 
de diagnose van de transferabiliteit van gegevens; de tweede fase is gericht op het 
aanpassen van gegevens zelf. Het onderzoek dat in dit proefschrift wordt beschre-
ven is gericht op het diagnosticeren van de transfereerbaarheid: het beoordelen in 
hoeverre gegevens verzameld in een bepaalde jurisdictie bruikbaar zijn in een ande-
re jurisdictie. Voor beleidsmakers is de diagnostische fase heel belangrijk, omdat ze 
op basis van een dergelijke beoordeling kunnen besluiten om gegevens uit andere 
jurisdicties te gebruiken of om eigen onderzoek te laten verrichten. Eigen onderzoek 
zal echter in de meeste gevallen duurder zijn en ook meer tijd kosten dan het ge-
bruik van economische evaluaties uitgevoerd in andere jurisdicties. Dus hoewel het 
gebruik van economische evaluaties uit andere jurisdicties soms noodzakelijk lijkt te 
zijn vanwege gebrek aan data uit de eigen jurisdictie, moet er kritisch worden geke-
ken naar de geschiktheid van deze data.  
 
In hoofdstuk 2 wordt geschetst dat een toenemende druk op beleidsmakers is ont-
staan om de schaarse middelen voor gezondheidszorg zo efficiënt mogelijk te be-
steden. Het is niet mogelijk om elke studie in de eigen jurisdictie uit te voeren, om-
dat dit wordt gezien als inefficiënt gebruik van middelen. Het gevolg is dat beleids-
makers moeten beoordelen of economische evaluaties die zijn uitgevoerd in andere 
jurisdicties geschikt zijn voor hun eigen beslissingscontext. Helaas kunnen de resul-
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taten van economische evaluaties vaak niet worden gebruikt zonder aanpassingen, 
aangezien zorgsystemen, juridische kaders en andere (transferabiliteits)factoren 
verschillen tussen jurisdicties. Het gevolg is dat economische evaluaties niet een-
voudig te transfereren zijn en dat beleidsmakers hier zich bewust van moeten zijn.  
 
Hoofdstuk 3 beschrijft het valideren van Welte’s model aan de hand van een casus. 
Het model van Welte is een methode om de transferabiliteit van economische eva-
luaties te beoordelen. Bij het beoordelen van de economische evaluaties worden in 
dit model algemene en specifieke uitsluitcriteria gebruikt. Door middel van een spe-
cifieke casus worden de resultaten van buitenlandse economische evaluaties ge-
transfereerd naar Nederland, waarbij twee verschillende methoden worden ge-
bruikt. De eerste methode gebruikt alle gevonden studies (alle studies voorspelling) 
en de tweede methode maakt alleen gebruik van de studies die de uitsluitcriteria 
van Welte passeren (Welte’s model voorspelling). Door te kijken naar de verschillen 
tussen de twee voorspellingen kan de werking van de uitsluitcriteria van Welte 
worden afgeleid. Vervolgens zijn deze voorspellingen vergeleken met een Neder-
landse referentie studie. Een inventarisatie van de literatuur leverde in totaal veer-
tien studies op. In de “alle studies voorspelling” zijn alle buitenlandse studies geïn-
cludeerd. In “Welte’s model voorspelling” zijn slechts zeven studies gebruikt, name-
lijk alleen studies die als transfereerbaar worden gezien. De resultaten van beide 
voorspellingen verschillen. Zo worden de kosten beter voorspeld in de “Welte’s 
model voorspelling”, maar worden de effecten beter voorspeld in de “alle studies 
voorspelling”. Daarom kan worden geconcludeerd dat het gebruik van Welte’s mo-
del de interpretatie van economische evaluaties beïnvloedt wanneer de transferabi-
liteit van economische evaluaties uit andere jurisdicties wordt beoordeeld.  
 
In hoofdstuk 4 kunnen verschillende aanbevelingen over het meenemen van pro-
ductiviteitsverliezen in economische evaluaties worden gezien in de verschillende 
nationale farmacoeconomische richtlijnen. De verschillen in aanbevelingen zijn het 
gevolg van het intense debat van de laatste twee decennia over het meenemen van 
productiviteitsverliezen in economische evaluaties. Richtlijnen zijn ontwikkeld om 
de opzet en de uitvoering van economische evaluaties aan te sturen. De aanbeve-
lingen in de dertig nationale richtlijnen die zijn bekeken verschillen in grote mate als 
het gaat om productiviteitsverliezen. Ten eerste, niet alle richtlijnen schrijven het 
gebruik van het maatschappelijke perspectief voor bij het uitvoeren van economi-
sche evaluaties. Daarnaast wordt in de meeste richtlijnen aanbevolen om de kosten 
van verzuim mee te nemen. Verder is er geen overeenstemming tussen de richtlij-
nen over de monetaire waardering van productiviteitsverliezen. Deze verschillen in 
aanbevelingen over het meest wenselijke studieperspectief en productiviteitsverlie-
zen vormen een groot obstakel bij het transfereren van gegevens naar andere juris-
dicties. Deze verschillende aanbevelingen over het meenemen en waarderen van 
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productiviteitsverliezen zijn waarschijnlijk het gevolg van het gebrek aan consensus 
over het includeren van productiviteitsverliezen in economische evaluaties.  
 
Volgend op het onderwerp van hoofdstuk 4, richt hoofdstuk 5 zich op de verschillen 
tussen landen wanneer dezelfde methode wordt gebruikt om productiviteitsverlie-
zen te meten bij eenzelfde populatie in alle jurisdicties. Om te onderzoeken of er 
significante verschillen in productiviteitslanden zijn tussen landen, hebben respon-
denten met een reumatische aandoening uit vier Europese landen - Nederland, 
Verenigd Koninkrijk, Frankrijk en Duitsland - een vragenlijst ingevuld op het internet. 
Deze vragenlijst bevat niet alleen vragen over productiviteitsverliezen, maar ook 
vragen over demografische kenmerken, werk en werkomstandigheden, ziekteken-
merken en kwaliteit van leven. De data zijn geanalyseerd met behulp van logistische 
en lineaire regressie, waarbij productiviteitsverliezen werden verklaard met behulp 
van de andere variabelen uit de vragenlijst. Uit de resultaten blijkt dat er tussen 
landen soms statistische significante verschillen in productiviteitsverliezen zijn, na-
melijk bij de uitkomstmaten ‘verzuim gedurende de laatste drie maanden’ en ‘kwali-
teit van werk gedurende de laatste werkdag’. Daarnaast hebben andere variabelen 
zoals kwaliteit van leven en werk en werkomstandigheden ook invloed op het ont-
staan en de hoeveelheid productiviteitsverliezen. Vanwege deze resultaten kan 
worden geconcludeerd dat het niet raadzaam is data over productiviteitsverliezen 
te transfereren. De consequentie is daardoor dat data omtrent productiviteitsverlie-
zen  moet worden verzameld in het land waar de data gebruikt zullen worden.  
 
De mogelijkheid om effecten uitgedrukt in kwaliteit van leven of utiliteiten te trans-
fereren wordt beschreven in hoofdstuk 6. Tot op heden was er weinig bekend over 
de mogelijke problemen bij het transfereren van utiliteiten tussen landen. De Euro-
QoL-5D (EQ-5D) is een veelgebruikt instrument bij economische evaluaties om ge-
zondheidstoestanden te beschrijven en het bestaat uit vijf domeinen met elk drie 
niveaus. Om uit die gezondheidstoestanden utiliteiten te berekenen zijn er verschil-
lende nationale algoritmen beschikbaar voor ieder land, de zogenaamde EQ-5D ta-
rieven. In dit hoofdstuk worden de verschillende nationale EQ-5D tarieven met el-
kaar vergeleken. De tarieven zijn vergeleken in verschillende stappen. Ten eerste is 
er gekeken naar het relatieve belang van de afzonderlijke domeinen van de EQ-5D 
en daarna naar de absolute en marginale utiliteiten van twee gezondheidstoestan-
den, te weten 21232 en 33321. Om de eventuele verschillen te verklaren is er ook 
gekeken naar de rol van de methodologische verschillen tussen de nationale EQ-5D 
tarieven. Verschillen werden gevonden tussen het belang dat landen hechten aan 
de vijf domeinen en daarbij werden de domeinen mobiliteit en angst/depressie als 
het belangrijkst gezien. Daarnaast zijn er grote verschillen gevonden tussen de utili-
teiten voor twee hypothetische gezondheidstoestanden. Het grootste verschil 
wordt gevonden tussen Spanje en Zimbabwe, waar het verschil 0,601 is op een 
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schaal van -1 tot 1,0. Verder zijn ook de verschillen tussen de marginale waarden 
substantieel. Deze verschillen tussen de nationale tarieven kunnen gedeeltelijk 
worden verklaard door de methodologische verschillen. Alle resultaten geven aan 
dat de verschillen tussen de EQ-5D tarieven, algoritmen om utiliteiten te bereken 
uit gezondheidstoestanden, aanzienlijk zijn.  
 
In de algemene discussie in hoofdstuk 7 werd het gehele proefschrift bediscussi-
eerd. Daarnaast zijn er aanbevelingen gedaan op het gebied van de transferabiliteit 
van economische evaluaties. Er kan ook geconcludeerd worden dat het onderzoek 
beschreven in dit proefschrift heeft geresulteerd in meer kennis over sommige as-
pecten van de transferabiliteit van economische evaluaties. Deze nieuwe kennis is 
gebruikt om een figuur te ontwikkelen waarin voor een aantal factoren de balans 
tussen de mate van transfereerbaarheid en de mate van generaliseerbaarheid is 
aangegeven. De data van de factor ‘absolute en relatieve prijzen’ zijn bijvoorbeeld 
niet direct te gebruiken en heeft dus een lage mate van generaliseerbaarheid. Het 
lijkt er echter op dat het tegenovergestelde geldt voor de factor ‘relatieve klinische 
effectiviteit’. Daarnaast is het duidelijk geworden dat het gebruik van Welte’s model 
om de transferabiliteit van economische evaluaties beoordelen leidt tot andere re-
sultaten dan het gebruik van buitenlandse data zonder beoordeling. De mate van 
transfereerbaarheid van twee factoren die de transferabiliteit beïnvloeden, namelijk 
utiliteiten en productiviteitsverliezen, is ook verduidelijkt. De resultaten geven ook 
aan dat aan transferabiliteit gerelateerde problemen deels het gevolg zijn van ver-
schillen in de aanbevelingen in nationale richtlijnen voor economische evaluaties. 
Deze verschillen tussen nationale richtlijnen kunnen verkleind worden door het 
ontwikkelen van een internationale farmacoeconomische richtlijn of een internatio-
nale referentie casus. De ontwikkeling van een internationale referentie casus is 
daarbij realistischer dan een internationale richtlijn. In zo’n referentie casus moeten 
alle elementen van een economische evaluatie op dezelfde manier worden bere-
kend en gerapporteerd. De mogelijkheid blijft echter bestaan om nationale elemen-
ten op te nemen in een economische evaluatie. Daarnaast zal een meer gestan-
daardiseerde manier om economische evaluaties uit te voeren ook voordeliger zijn 
voor kleine landen en voor minder welvarende landen. Standaardisatie maakt het 
eenvoudiger om de transferabiliteit van studies te beoordelen. Verder worden er 
ook een aantal aanbevelingen voor meer onderzoek gegeven. Een van de aanbeve-
lingen is om een nieuwe methode voor de beoordeling van de transferabiliteit van 
economische evaluaties te ontwikkelen. In deze nieuwe methode moeten ook de 
laatste inzichten op het gebied van transferabiliteit worden meegenomen. Daar-
naast zal meer onderzoek zich moeten richten op de mate van transfereerbaarheid 
van andere factoren en op de ontwikkeling van een adaptatie-instrument. Met een 
adaptatie-instrument kunnen de data verzameld in een specifieke jurisdictie zo 
worden aangepast dat het in een andere jurisdictie kan worden gebruikt. Door de 
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resultaten in dit proefschrift wordt het belang van transparant rapporteren van 
economische evaluaties en het belang van transparantie bij het beoordelen van de 
transfereerbaarheid van economische evaluaties aangetoond. Aangezien op deze 
manier meer duidelijkheid zal bestaan over de transfereerbaarheid van economi-
sche evaluaties.  
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